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         http://www.cost.eu/ 
 
COST is an intergovernmental framework for European Cooperation in Science and 
Technology, allowing the coordination of nationally-funded research on a European level. 
COST has a very specific mission and goal. It contributes to reducing the fragmentation in 
European research investments and opening the European Research Area to cooperation 
worldwide. 
 
 
 
  
http://www.stemchem.org/ 
 
CMST COST Action CM1106  
http://www.cost.eu/domains_actions/cmst/Actions/CM1106 
From Memorandum of Understanding: 
This COST Action aims to unite researchers with expertise in rational drug design and the 
medicinal chemistry of synthetic and natural compounds with biomedical investigators 
dedicated to the understanding the mechanisms governing drug resistance in cancer stem 
cells. Through exchange of information, experience and expertise, researcher mobility and 
fostering new collaboration between chemistry and biology groups, the Action endeavours to 
develop new, effective methods for identifying novel compounds and drug candidates that 
target drug-resistant cancer stem cells. 
 
 
               
                                            https://www.ipatimup.pt/ 
  
 
The Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) is 
a private non-profit association of public utility, established in 1989 under the aegis of the 
University of Porto. IPATIMUP is an Associated Laboratory of the Ministry of Science and 
Higher Education since 2000. 
IPATIMUP aims to understand the causes and evolution of human oncologic diseases to go 
forward in early diagnosis, maximize treatment efficiency, improve the quality of patients’ life 
and reduce cancer incidence in the population. 
IPATIMUP strands of activity are: Research on Oncology and Population Genetics, through the 
interaction of several scientific domains (Medicine, Biology, Genetics, Pharmacy and 
Biophysics); Development of human resources specialized in Oncology and Oncobiology; 
Diffusion of Science, thus contributing to the population’s scientific culture; Specialized 
diagnostic and consultation services on cancer issues. 
 
 
 
 
              Additional Sponsoring by: 
Cover photograph: Nuno Ribeiro                 http://www.bdbiosciences.com/   
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21st February 2013 
08h30  Registration 
09h15  Introduction: Gabriela Almeida (IPATIMUP, Portugal) 
            Daniele Passarella (Università degli Studi di Milano, Italy)  
Section I:  Chairman: James Lorens (University of Bergen, Norway) 
09h30  Christel Herold-Mende Div. Exp. Neurosurgery, Univ. of Heidelberg, Germany 
Aberrant self-renewal and quiescence contribute to glioblastoma 
aggressiveness  
09h50  Panagiota Sotiropoulou IRIBHM, Université Libre de Bruxelles, Belgium  
Differential resistance of distinct types of stem cells to DNA damage 
10h10  Magdalena Król Warsaw University of Life Sciences - WULS, Poland 
mRNA and microRNA expression profiling of canine mammary carcinoma cell 
lines and tumor-associated macrophages grown as a co-culture in vitro 
10h30  Richard Clarkson Cardiff University School of Biosciences, UK – Invited Expert 
TRAIL mediated targeting of breast cancer stem cells in a model of acquired 
drug resistance 
10h50   Coffee break 
11h15  Welcome: Manuel Sobrinho Simões (IPATIMUP, Portugal) 
11h20  M. Angela Nieto Instituto de Neurociencias CSIC-UMH , Spain - Invited Expert  
The reversibility of the EMT in development and cancer progression 
12h05  James Lorens University of Bergen, Norway 
Axl receptor signaling in required for EMT-associated stem cell and malignant 
traits in cancer    
12h25  Joana Paredes IPATIMUP and FMUP, University of Porto, Portugal 
P-cadherin: a stem cell marker overexpressed in high-grade breast carcinomas 
12h45   Lunch and Poster Session I 
Section II: Chairman: Danijel Kikelj (University of Ljubljana, Slovenia) 
14h45  Antonello Mai  Università “La Sapienza” di Roma, Italy - Invited expert  
Assessing Sirtuins as Drug Targets in Human Illnesses 
15h30  Ruta Navakauskiene Institute of Biochemistry, Vilnius University, Lithuania 
Effects of HDACI, HMTI and HMTI in combination with retinoic acid on 
granulocytic differentiation of human promyelocytic leukemia cells  
15h50  Annalisse Cassar University of Malta, Malta 
Effects of Insect Conditioned Medium in Combination with Chromatin-
Modifying Agents on the Terminal Differentiation of Leukaemia 
16h10  Coffee break and Poster Session I 
16h45 – 18h00 MC meeting: Only for the members of the Management Committee  
19h15  Bus departure from Conference Hotels to Conference Dinner 
20h30  BD sponsored Conference Dinner – Caves Taylor (Port Wine Cellars)  
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22nd February 2013 
Section III:  Chairman: Daniele Passarella (Università degli Studi di Milano, Italy) 
09h15  Nadine Martinet Institute of chemistry, Nice, France - Invited Expert 
The essential epigenetic Compound library  
10h00  Bruno Botta Università “La Sapienza” di Roma, Italy 
Natural lead products inhibit the Hedgehog signaling pathway in 
medulloblastoma 
10h20  Ferenc Hudecz Eötvös Lorand University, Budapest, Hungary 
Oligopeptide bioconjugates: synthesis, characterization and use for antitumour 
drug targeting  
10h45  Coffee break 
11h20  M. Helena Vasconcelos FFUP and IPATIMUP, Porto, Portugal 
A new small molecule with antitumour and chemosensitizing potential as P-gp 
inhibitor 
11h40  Attila Hunyadi Institute of Pharmacognosy, University of Szeged, Hungary 
Activity of ecdysteroid and protoflavone derivatives on MDR cancer cells 
12h00  Graça Soveral Faculty of Pharmacy, University of Lisbon, Portugal 
Aquaporin channels as targets for cancer therapy 
12h20  Lunch and Poster Session II  
Section IV: Chairman: Maurizio Botta (Università degli Studi di Siena, Italy) 
14h20  Carlo Unverzagt Universität Bayreuth, Bayreuth, Germany 
Carbohydrates on and around cancer stem cells  
14h40  Juraj Kóňa Inst. of Chemistry, Slovak Acad. Sciences, Bratislava, Slovak Republic 
How to improve predictive accuracy of a QSAR model for the design of 
inhibitors of sugar processing enzymes with transition metal ion co-factors  
15h00 Rosanna Dono Aix-Marseille University - IBDML, Marseille, France  
Forcing cancer stem cells to behave: GLYPICAN4 as potential molecular target 
to trigger cancer stem cell differentiation 
15h20  Presentation of Selected Posters (5 presentations, 5 min each) 
15h50  Coffee break and Poster Session II 
16h20  Round Table Discussions: Chairmen: Daniele Passarella, James Lorens and 
Wolfgang Link 
High throughput screening for novel CSC targeted molecules   
18h00   Closing Remarks 
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Poster Session I 
P1. Agata Homa (Department of Physiological Sciences, Faculty of Veterinary Medicine, 
Warsaw University of Life Sciences-WULS, Warsaw, Poland) miRNA expression in canine 
mammary cancer stem cells 
 
P2. Ana Čipak Gašparović (Rudjer Boskovic Institute, Zagreb, Croatia) Oxidative 
modifications of extracellular matrix change Hedgehog signaling patway 
 
P3. Ana Mitanoska (Faculty of Natural and Technical Science, University Goce Delcev - Stip, 
Stip, Republic of Macedonia) Developing of inducible cell lines for study gene gain of function  
 
P4. Andreani Odysseos (EPOS-Iasis, R&D and University of Cyprus, Cyprus) Quantitative 
phosphoproteomics dissects sensitization of EGFR-resistant colon cancer cells to Tyrosine 
Kinase Inhibitors through Spliceosome Modulation 
 
P5. Bernd Groner (Georg Speyer Haus, Institute for Biomedical Research, Frankfurt am Main, 
Germany) The functional interplay between activated Stat5 and Stat3 in breast cancer 
formation and progression and the therapeutic effects of targeted inhibition 
 
P6. Daniele Lo Re (School of Chemistry, National University of Ireland Galway, Galway, 
Ireland) Synthesis of Multi Drug Resistance modulators based on jatrophane framework 
 
P7. Danijel Kikelj (University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia) Dual 
antithrombotic compounds with antiangiogenic activity as potential potential approach to 
targeting cancer stem cells 
 
P8. Engin Ulukaya (Uludag University, Medical School, Department of Medical Biochemistry, 
Bursa, Turkey) Differential Cytotoxic Activity of a Novel Palladium-Based Compound on 
Prostate Cell Lines, Primary Prostate Epithelial Cells and Prostate Stem Cells 
 
P9. Flavio Maina (Aix-Marseille University – Developmental Biology Institute of Marseille-
Luminy (IBDML) – CNRS UMR7288, Marseille, France) Abl acts as a “signalling node” for 
maintenance, propagation, and motility of glioblastoma cells 
 
P10. Giovanna Damia (Department of Oncology, Istituto di Ricerche Farmacologiche “Mario 
Negri”, Milan, Italy) ALDH enzymatic activity and CD133 positivity in ovarian cancer patients 
 
P11. Ioannis S.Vizirianakis (Laboratory of Pharmacology, Department of Pharmaceutical 
Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece) Development of a novel 
mesoporous carbon drug delivery system: Characterisation and cytocompatibility studies 
 
P12. Juraj Dobiáš (Comenius University, Faculty of Natural Sciences, Dep. of Organic 
Chemistry, Bratislava) TKI Inhibitors in Targeting Cancer Stem Cells – Development of New KDR 
Inhibitor 
 
P13. Katarzyna Wnuk-Lipinska (University of Bergen, Bergen, Norway) Targeting cancer 
stem cells with an Axl inhibitor 
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P14. Lidija Milkovic (Rudjer Boskovic Institute, Zagreb, Croatia) Cell type-dependent response 
to chemotherapy treatment with doxorubicin in breast cancer 
 
P15. Patrícia Oliveira (Institute of Molecular Pathology and Immunology of the University of 
Porto, IPATIMUP, Porto, Portugal) Using an in vitro model of Epithelial-Mesenchymal-Epithelial 
transitions to uncover novel biological mechanisms 
 
P16. Sabrina Dallavalle (Department of Food, Environmental and Nutritional Sciences, 
Università di Milano, Milano, Italy) New captothecin-linked platinum anticancer agents 
 
P17. Sara Toscano (Dipartimento di Chimica e Tecnologie del Farmaco, Università “La 
Sapienza” di Roma; IIT Center for Life Nano Sciences, CLNS@Sapienza, Roma, Italy) Natural 
lead products inhibit the Hedgehog signaling pathway in medulloblastoma 
 
P18. Veronika Borutinskaite (Department of Molecular Cell Biology, Institute of 
Biochemistry, Vilnius University, Vilnius, Lithuania) Studies of the DNA methyltransferases 
inhibitor EGCG effects on human leukemia cell proliferation and differentiation 
 
     
 
 
Poster Session II 
P1. Ana Martins (University of Szeged, Szeged, Hungary and Universidade Nova de Lisboa, 
Lisbon, Portugal) Novel ecdysteroids as modulators of multi-drug resistance 
 
P2. Andreia Sousa (Institute of Molecular Pathology and Immunology of the University of 
Porto, IPATIMUP, Porto, Portugal) MUC1: uncovering a new target for pancreatic cancer 
therapy 
 
P3. Anna Lucia Fallacara (Dipartimento di Biotecnologie, Chimica e Farmacia, University of 
Siena, Italy) Design, Synthesis and Biological Evaluation of Pyrazolo[3,4-d]pyrimidines Active in 
vivo on Bcr-Abl mutant 
 
P4. Bruno Pereira (Institute of Molecular Pathology and Immunology of the University of 
Porto, IPATIMUP, Porto, Portugal) CDX2 regulation by the RNA-binding protein MEX3a: impact 
on intestinal differentiation and stemness 
 
P5. Constantinos M. Athanassopoulos (Laboratory of Synthetic Organic Chemistry, 
Department of Chemistry, University of Patras, Patras, Greece) Total Synthesis of Acidic 
Retinoids: A Library of Potential Cancer Stem Cell Regulators 
 
P6. Daniela P. Freitas (Institute of Molecular Pathology and Immunology of the University of 
Porto, IPATIMUP, Porto, Portugal) Drug-induced enrichment of putative cancer stem-like cells 
for the identification of potential therapeutic targets to overcome their chemoresistance  
 
P7. Darko Bosnakovski (Faculty of Medical Sciences, University Goce Delcev - Stip, Stip, 
Republic of Macedonia) Stem cell based high-throughput screen to identify inhibitors of DUX4 
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P8. Dušan Sladić (University of Belgrade – Faculty of Chemistry, Belgrade, Serbia) Anti-
metastatic and anti-angiogenic properties of potential new anti-cancer drugs based on metal 
complexes of selenosemicarbazones 
 
P9. Emmanuel N. Pitsinos (Laboratory of Natural Products Synthesis & Bioorganic 
Chemistry, NCSR “DEMOKRITOS”, Athens, Greece) Synthesis of Taepeenin D analogues as 
potential cancer stem cell-targeted agents 
 
P10. Gilles Hanquet (Laboratoire de Stéréochimie associé au CNRS, ECPM, Université de 
Strasbourg, Strasbourg, France) A Straightforward access to an advanced precursor of 
Triptolide and analogues 
 
P11. José M. Padrón (BioLab, Instituto Universitario de Bio-Orgánica "Antonio González", 
Universidad de La Laguna, La Laguna, Tenerife, Spain) Mechanism of action the novel tubulin 
destabilizing agent DTA0100 
 
P12. Katarina Anđelković (University of Belgrade – Faculty of Chemistry, Belgrade, Serbia) 
Synthesis, characterization, cytotoxic and antioxidative activity of d-metal complexes with 2,6-
diacetylpyridine bis(selenosemicarbazone) 
 
P13. Maria M. M. Santos (Research Institute for Medicines and Pharmaceutical Sciences, 
Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal) Targeting the wt p53: synthesis of 
a new family of modulators 
 
P14. Mark P. Farrell (School of Chemistry, National University of Ireland, Galway, Ireland) 
Anomerisation of Glycosidic linkages using Titanium(IV) Chloride 
 
P15. Michael Christodoulou (Dipartimento di Chimica, Università degli Studi di Milano, 
Milano, Italy) Camptothecin scaffold modification: synthesis and biology 
 
P16. Mehdi Ghassemi (Bilkent University, Ankara, Turkey) In silico prediction and in vitro 
validation of biomarkers for chemosensitivity to src inhibitors in melanoma cell lines 
 
P17. Stella Borrelli (Università degli Studi di Milano, Dipartimento di Chimica, Milano, Italy) 
Novel nanoassemblies of known anticancer compounds by coupling with squalene moiety 
 
P18. Wolfgang Link (Regenerative Medicine Program, Department of Biomedical Sciences 
and Medicine, University of Algarve, Faro, Portugal) Learning old tricks from viruses to fight 
cancer 
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Aberrant Self-Renewal and Quiescence Contribute to Glioblastoma 
Aggressiveness 
 
Christel Herold-Mende 
Division of Experimental Neurosurgery, University of Heidelberg, INF 400, 69120 Heidelberg 
 
 
Stem-like tumor cells endowed with enhanced self-renewal capacity are believed to drive 
tumor growth in malignant gliomas. So far a variety of surrogate markers has been proposed 
to characterize and enrich these cells emphasizing the need of devising new isolation methods 
based on common functional and phenotypic criteria.  
In this study we made use of a collagen-based self-renewal assay, to screen for clonogenic cell 
subpopulation in malignant gliomas. Cells were profiled using a gene expression chip and 
tested for tumor formation capacity in an orthotopic mouse model. Label retention was used 
to detect quiescent tumor cells.  
In a panel of glioblastoma cell lines (n=21) we identified several cell lines enriched for cells 
with enhanced self renewal capacity. These cell lines were capable of matrix-independent 
growth and formed fast-growing, orthotopic tumors in mice. Employing isolation and re-
plating techniques, we could further show that these cells invariably re-established a cellular 
hierarchy through a series of asymmetric cell divisions. However, the ratio of symmetric to 
asymmetric cell divisions seemed to be pathologically increased and was linked to idiosyncratic 
transcriptomal changes as well as to poor overall survival of corresponding patients. Finally, 
through label-retention experiments we further identified a subpopulation of quiescent and 
chemo-resistant cells, which retained the ability to reinitiate growth of secondary cell clones 
and thus, might play a role in tumor recurrence after therapy.  
Conclusions: Altogether, our results suggest tumor quiescence and aberrant proliferations 
influence the aggressiveness of glioblastoma. 
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Differential resistance of distinct types of stem cells to DNA damage 
 
Peggy Sotiropoulou 
IRIBHM, Université Libre de Bruxelles 
 
 
The accurate maintenance of genomic integrity is essential for tissue homeostasis and its 
deregulation leads to cancer and ageing. We used as a model the skin epidermis, which is 
maintained by distinct pools of stem cells (SCs). Upon irradiation-induced DNA damage, the 
hair follicle bulge SCs are profoundly resistant to irradiation-induced cell death due to high 
expression of the anti-apoptotic Bcl2, and more efficient non-homologous end-joining repair 
mechanism. On the other hand, conditional deletion in the epidermis of Brca1, crucial for DNA 
repair and critical mediator of the choice of the repair pathway, resulted in specific loss of the 
hair follicle bulge SCs, while the rest types of epidermal SCs remained unaffected.  
Enhanced DNA repair and resistance to apoptosis have been shown for several types of cancer 
SCs, albeit usually in vitro, and for this reason cancer SCs have been accused for tumour 
relapse after therapy. Using genetic lineage-tracing in squamous cell carcinoma, we showed 
that benign papillomas exhibit two distinct proliferative cell compartments, mirroring the 
normal tissue hierarchy, while   invasive malignant carcinomas grow with geometric expansion 
of a single cancer SC population. Further studies following the fate of cancer SCs upon 
treatment and tumour relapse are needed in order to show the response of cancer SCs to 
therapy and to design successful anti-cancer treatments. 
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mRNA and microRNA expression profiling of canine mammary carcinoma 
cell lines and tumor-associated macrophages grown as a co-culture in 
vitro 
 
Magdalena Król1, Karol Pawłowski2, Kinga Majchrzak3, Alicja Majewska1,  
Tomasz Motyl1 
1
Department of Physiological Sciences, Faculty of Veterinary Medicine,  Warsaw University of 
Life Sciences - WULS, Nowoursynowska 159, 02-776 Warsaw, Poland 
2
Department of Large Animal Diseases with Clinic, Faculty of Veterinary Medicine, Warsaw 
University of Life Sciences – WULS, Nowoursynowska 100, 02-797 Warsaw, Poland 
3
Department of Animal Environment Biology, Faculty of Animal Sciences,  Warsaw University of 
Life Sciences - WULS, Ciszewskiego 8, 02-786 Warsaw, Poland 
 
 
Solid tumors comprise various cells, including cancer cells, resident stromal cells, migratory 
haemopoietic cells and other. These cells regulate tumor growth and metastasis. Macrophages 
constitute probably the most important element of all interactions within the tumor 
microenvironment. However, the molecular mechanism, that guides tumor environment, still 
remains unknown. Exploring the underlying molecular mechanisms that orchestrate these 
phenomena has been the aim of our study. 
The co-cultures of five various canine mammary carcinoma cell lines and macrophages were 
established and maintained for 72 hrs. After that, having sorted the cancer cells, an integrated 
analysis of genome-wide mRNA and microRNA expression profiles have been assessed.  
The analysis showed that the up-regulated genes in the cancer cell lines are involved mainly in: 
macrophages activation, cell motion, mammary gland development, cell-cell adhesion, and 
angiogenesis. The presence of macrophages in the cancer environment induces acquisition of 
the macrophage antigens and phenotype in cancer cells.  
The findings of miRNA expression are in accordance with results obtained at mRNA level.  
Our analysis identified a number of pathways and processes that are up-regulated in cancer 
cells by the presence of macrophages. Taken together, this integrated comparative study 
generated a sketch of the molecular changes that occur during interactions between 
macrophage and cancer. Because as far as we realize this is the first analysis of changes in 
miRNA expression in cancer cells due to a presence of macrophages, our study can serve as a 
valuable source for future studies on a tumor microenvironment, and some of the highlighted 
genes, miRNAs, pathways or processes may be useful for diagnostic or therapeutic purposes in 
the future. 
This work was supported by grant no N N308012939 from the Ministry of Sciences and Higher 
Education. 
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TRAIL mediated targeting of breast cancer stem cells in a model of 
acquired drug resistance 
 
Luke Piggott1, Julia Gee2, Rhiannon French1 and Richard Clarkson1 
Schools of 
1
Biosciences and 
2
Pharmacy, University of Cardiff, Cardiff, Wales. 
 
 
TRAIL is a naturally occurring peptide that selectively induces apoptosis in tumour cells.  TRAIL 
analogues/agonists are undergoing clinical trials for a number of cancer types and the current 
indications are that these agents have relatively poor overall clinical efficacy, but with a 
minority of patients experiencing marked clinical improvement.  The general consensus is 
therefore that TRAIL could be of benefit if appropriately targeted to responsive disease sub-
groups. 
It is widely accepted that breast cancers are refractory to TRAIL cytotoxicity and thus breast 
cancer patients are not regarded as a target group for this new therapeutic.  We have 
investigated the underlying causes of this TRAIL resistance in breast cancer cells and have 
found that the endogenous TRAIL inhibitor c-FLIP is responsible for this resistance.  In cell-line 
based work, suppression of c-FLIP by RNAi sensitized all sub-types of breast cancer tested to 
TRAIL killing, and selectively eliminated cancer stem cell-like activity (determined by 
tumoursphere culture and tumour initiation studies in xenografts) from the tumour cell 
populations.  This has important implications for long-term therapy. 
Furthermore we have shown that breast cancer cells that have acquired resistance to anti-
hormone agents (eg. Tamoxifen, Faslodex) gain an inherent susceptibility to TRAIL alone, and 
that this correlates with a reduction in levels and/or subcellular redistribution of c-FLIP in the 
cytosol of tumour cells.  Once again, cancer stem cell-like activity was eliminated from these 
populations and systemic TRAIL treatment of mice bearing tumours with acquired endocrine 
resistance displayed a profound and persistent tumour relapse.  We are currently investigating 
whether this therapeutic effect can be recapitulated in ex vivo primary breast tumours derived 
from patients who have relapsed on endocrine therapy, and whether c-FLIP could be used as a 
biomarker of this TRAIL-responsive disease group. 
These studies suggest that TRAIL might in the future be indicated for ER positive breast cancer 
patients with relapsed disease.  We also propose c-FLIP as a new drug target and potential 
biomarker for breast cancer. 
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The reversibility of the EMT in development and cancer Progression 
 
M. Angela Nieto 
Instituto de Neurociencias CSIC-UMH, 03550 San Juan de Alicante, Spain 
anieto@umh.es 
 
 
The epithelial to mesenchymal transition (EMT) is required in the embryo for the formation of 
tissues which cells originate far from their final destination. This programme endows cells with 
migratory and invasive properties. Interestingly, the reverse process, known as mesenchymal 
to epithelial transition (MET), is also essential in embryogenesis to allow the differentiation of 
tissues and organs once the embryonic migratory cells reach their final destination. The 
pathological activation of the EMT programme in the adult promotes tumour progression and 
organ fibrosis and recent findings indicate that the EMT can also confer stem cell properties. 
Similar to the situation in embryos, it has been suggested that a reversion of the EMT (MET) 
might also be necessary for metastatic colonization once malignant cells extravasate and find 
their niche in distant organs. 
The main inducers of the EMT are transcription factors of the Snail, Zeb and Twist families 
(EMT-TFs). Recently, we have identified a novel EMT inducer expressed in a subset of lateral 
plate mesodermal (lpm) cells devoid of Snail1 and Snail2, the main EMT-TFs expressed during 
early mesoderm development. Gain of function experiments in zebrafish embryos show a 
dramatic phenotype, whereby lpm cells become invasive and violate the embryonic 
boundaries to enter the extraembryonic tissues. By contrast, loss of function experiments 
prevent the migration of the mesodermal cells, failing to colonize their normal territory.  
Silencing experiments in mesenchymal cancer cells induce a full MET. I will discuss that MET is 
required for cancer cells to metastasize in vivo, concomitant with the acquisition of stem cell 
properties. These findings have important implications both in terms of the differentiation of 
embryonic stem cells, reprogramming and metastatic colonization. 
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Axl receptor signaling in required for EMT-associated stem cell and 
malignant traits in cancer 
 
James Lorens 
Department of Biomedicine, University of Bergen, Bergen, Norway 
 
 
Epithelial-to-mesenchymal transition (EMT) endows carcinoma cells with migratory, survival 
and stem cell-like attributes that facilitate therapeutic resistance and metastasis. Expression of 
the Axl receptor tyrosine kinase in aggressive cancers correlates with EMT, drug resistance, 
metastasis and poor patient survival. Induction of EMT in immortalized mammary epithelial 
cells by EMT-transcription factors, TGFbeta or hypoxia upregulates Axl and establishes an 
autocrine-signaling loop with its ligand, Gas6. Axl receptor signaling is required to maintain 
EMT-related invasive, drug resistance and cancer stem cell (CSC) traits of malignant breast 
cancer cells. Targeting Axl signaling with RNAi or pharmacological agents blocks the EMT/CSC 
gene program and inhibits malignant functions including invasiveness, drug resistance, 
mammosphere formation, in vivo tumor initiation, and spontaneous metastasis in orthotopic 
breast cancer models. These results suggest that Axl expression is requisite for the 
maintenance of cancer stem cell-like traits during malignant progression. The EMT program is 
characteristic of normal adult mammary epithelial stem/progenitor cells. Congruently, we 
show that the Axl receptor expressed on mammary epithelial stem/progenitor cells, and Axl 
signaling is necessary for mammary epithelial multipotent progenitor activity. Thus Axl 
receptor signaling represents a novel regulatory pathway linking normal mammary 
stem/progenitor cells and breast cancer stem cells. Clinical Axl inhibitors represent a novel 
therapeutic avenue to target EMT/CSC traits of aggressive breast cancer. 
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P-cadherin: a stem cell marker overexpressed in high-grade breast 
carcinomas 
 
Ana Sofia Ribeiro1, André Filipe Vieira1, Bárbara Sousa1, Ana Rita Nobre1, André 
Albergaria1,2, Raquel Seruca1,2, Fernando Schmitt1,2, Joana Paredes1,2 
1
Cancer Genetics, IPATIMUP – Institute of Molecular Pathology and Immunology of the 
University of Porto, Porto, Portugal; 
2
Faculty of Medicine of the University of Porto, Porto, 
Portugal. 
 
 
P-cadherin is a cell-cell adhesion molecule, whose expression is highly associated with 
undifferentiated cells in normal adult epithelial tissues. In fact, its expression has been already 
reported in human embryonic stem cells and it is presumed to be a marker of stem or 
progenitor cells of some epithelial tissues [1,2].  
In breast cancer, our group has found that P-cadherin is frequently overexpressed in high-
grade tumors, being a well-established indicator of poor patient prognosis [3,4,5]. Additionally, 
it has been shown as an important inducer of cancer cell migration and invasion, with 
underlying molecular mechanisms involving the signaling mediated by its juxtamembrane 
domain, the secretion of matrix metalloproteases to the extracellular media, and the cleavage 
of a P-cadherin soluble form with pro-invasive activity [6,7]. Intracellularly, we found that this 
protein interferes with the endogenous cadherin/catenin complex, inducing p120-catenin 
delocalization to the cytoplasm, and the consequent activation of Rac1/Cdc42 and associated 
alterations in the actin cytoskeleton [8]. Furthermore, our recent data supports the idea that 
P-cadherin confers stem cell properties to breast cancer cells, surviving in anchorage 
independent conditions and resisting to radiotherapy [9]. This association between P-cadherin 
and signalling involved in invasion, stemness and survival were validated by microarrays [8], 
turning this protein as a putative therapeutic target for invasive carcinomas overexpressing 
this protein. 
 
 
Acknowledgements: This study was mainly supported by scientific projects funded by FCT (Fundação 
para a Ciência e Tecnologia, Portugal) (PTDC/SAU-GMG/120049/2010; POCI/BIA-BCM/59252/2004), and 
by a grant funded by Fundação Gulbenkian (Project 96633-2010).  
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Assessing Sirtuins as Drug Targets in Human Illnesses 
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NAD+-dependent histone deacetylases (sirtuins, SIRT1-7) have emerged as potential 
therapeutic targets for treatment of human illnesses such as cancer, metabolic, cardiovascular 
and neurodegenerative diseases. In our lab, several chemically different series of sirtuin 
inhibitors (SIRTi) have been identified and will be further developed.  
The first series comprises some sirtinol analogues, obtained by replacement of the benzamide 
linkage of the prototype with other bioisosteric groups. Such compounds showed higher 
apoptosis induction and/or higher cytodifferentiation than sirtinol in human leukemia U937 
cells. One of them, salermide, was well tolerated by mice, prompted tumor-specific apoptosis 
and antiproliferative effects in human cancer cells. Starting from cambinol, a SIRTi reported as 
highly active against the Burkitt lymphoma, we designed some (thio)barbituric acid analogues 
(BDF4s) related to cambinol to evaluate as SIRTi and anticancer agents. The BDF4 prototype, 
MC2141, displayed in U937 cells higher apoptosis induction than cambinol and showed 
antiproliferative effects against a panel of cancer cells. More recently we devoted our 
attention to AGK-2, a SIRT2-selective inhibitor useful in a Parkinson disease model. We 
designed and synthesized some AGK-2 analogues, called acylpyrrolyliden-cyanacetamides 
(APCs) bearing an acylpyrrole moiety instead of the phenylfuran group of AGK-2, and we 
started to study the effect of substitution at the pyrrole as well as cyano and/or quinoline level 
on the SIRT inhibiting activity. MC2494, a prototype of the APC series, gave significant 
apoptosis induction in a series of cancer cells, while AGK-2 failed in the same conditions. Some 
our SIRTi belonging to different chemical classes and studied as anticancer agents were tested 
against colon and glioblastoma cancer stem cells (CSCs), obtaining in some cases excellent 
antiproliferative activity. 
In contrast to the number of SIRT inhibitors, only few SIRT1 activators are known. Here, we 
rationalized the potential of the previously unexplored dihydropyridine scaffold to develop 
sirtuin ligands by preparing a series of 1,4-dihydropyridine-based (DHP) derivatives. 
Assessment of their SIRT1-3 deacetylase activities revealed the importance of the substituent 
at the N1 position of the dihydropyridine structure on sirtuin activity. Introduction of 
cyclopropyl, phenyl, or phenylethyl groups at N1 conferred non-selective SIRT1 and SIRT2 
inhibition activity, while a benzyl group at N1 conferred potent SIRT1 and -2 activation. 
Senescence assays performed on hMSC, and mitochondrial function studies conducted with 
murine C2C12 myoblasts confirmed the compounds’ novel and unique SIRT-activating 
properties. One of DHPs, MC2791, tested against colon carcinoma cell lines, showed high 
antiproliferative activity. To assess the effect of selected DHPs during angiogenesis and would 
healing following skin damage, a series of experiments were performed in mice after 
cutaneous punch-biopsy. In vitro experiments revealed that SIRT activation stimulated 
proliferation of endothelial cell, keratynocytes and skin fibroblasts paralleled by the induction 
of eNOS phosphorylation and nitric oxide (NO) production.  
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Effects of HDACI, HMTI and HMTI in combination with retinoic acid on 
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Differentiation therapy is the most promising strategy in the haematology oncology. The 
human leukaemia cell lines have been used repeatedly as a model to study the control 
mechanisms of proliferation, differentiation and apoptosis. These exponentially growing 
neoplastic cells can be induced to differentiate into granulocytes by treatment with chemical 
agents such as all-trans retinoic acid (RA) or its isomer and other agents. In our work we 
examine the anti-leukemic effects of novel chemical agents such as HDACI (belinostat, 
phenylbutyrate etc.), DNMTI (RG108, Zebularine, EGCG etc.), HMTI (3-DZNeplanocin A) that 
are potential for modulating chromatin and genes of myeloid origin in combination with RA.   
We observed that combined treatment and/or pre-treatment with epigenetic modifiers 
(HDACI, DNMTI, HMTI) before the induction of differentiation with all-trans retinoic acid leads 
to more effective and accelerated granulocytic differentiation of leukemic cells. Differentiation 
level was assessed by NBT reduction and confirmed by the expression of the early myeloid 
differentiation marker CD11b. It was also demonstrated that combinations of these agents 
arrests cells in the G0/G1 phase of the cell cycle. Terminal granulocytic differentiation of human 
promyelocytic leukaemia cells is associated with HDAC, HMT, DNMT, C/EBP genes expression 
modulation. We also demonstrated that changes in histone modifications (histone H4 
acetylation, histone H3K4me3) are associated with induction of granulocytic cell 
differentiation. These results suggest that combination of used agents might have potential in 
promyelocytic leukaemia differentiation therapy.  
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Effects of Insect Conditioned Medium in Combination with Chromatin-
Modifying Agents on the Terminal Differentiation of Leukaemia 
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Leukaemia is the most common type of cancer that occurs in children worldwide. Despite the 
intense research carried out in several facilities, acute myeloid leukaemia is still considered the 
highest cause of cancer death in children to young adults with a long-term survival rate of only 
approximately 10%. The successful use of retinoic acid in the treatment of acute promyelocytic 
leukaemia has prompted further research of differentiation therapy to include other 
leukaemia sub-types. The rationale is to force leukaemia cells into entering the apoptotic 
pathway by undergoing terminal differentiation rather than use cytotoxic drugs to treat this 
cancer. 
Media conditioned from cells of an insect pupa has already been proven to effect the 
differentiation of the HL60 cell line. Now we aim to expand these results to other leukemia cell 
lines with the aid of chromatin-modifying agents. 
The organic fraction of the insect conditioned medium was used to treat various Leukaemia 
cell lines including KG-1a, K562 and NB4-R2, with and without histone deacetylase inhibitors 
and the DNA demethylator 5’Azacytidine. 
Differentiation was assessed through reduction of nitroblue tetrazolium and results were 
normalized using the MTT assay. 
Where the insect conditioned medium did not cause a strong differentiation effect, 
pretreatment with histone deacetylase inhibitors considerably improved the result. This 
implies that the insect conditioned medium extract has a possible application in the treatment 
of different leukaemia sub-types other than acute promyelocytic leukaemia. The next step will 
be to test the insect conditioned medium, and successful combinations with chromatin-
modifying agents, on patient primary cells in the hope of formulating a novel drug that will 
help in the treatment of leukaemia. 
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The essential epigenetic Compound library 
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During Cost TD 0905 ‘Epigenetic from bench to bedside’ some researchers provided published 
compounds but also new ones. We used them to build a compound library. 
In parallel, biologist offered screening for biological activities: HDAC, sirtuin, PRMT, DNA 
methylation, HAT (pan screening first and then specific screening for the hits). 10 different 
screens have been achieved. In silico screen is also beginning for HDAC, sirtuin and DNA 
methylation. Some assays were new. 
With the first results, we built EITeen:an Initial training network for epigeneticist. 400 
compounds were screened and 40 make the essential library with well characterized 
standards. An example of a new assay for multidrug resistance will be given. 
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The medulloblastoma is the most frequent malignant brain tumor of childhood, it belongs to 
the group of embryonal neuroepithelial tumors and arise from stem cells or early progenitor 
cells in the cerebellum1. The Hedgehog pathway (Hh) is an essential embryonic signalling 
cascade that regulates stem-cell and progenitor-cell differentiation in multiple developmental 
processes. Smoothened homologue (SMO) is a transmembrane protein that activates the 
downstream Hedgehog signaling pathway. PTCH1 is an inhibitory cell-surface receptor that 
constitutively suppresses activation of the hedgehog pathway by inhibiting SMO. Hedgehog 
ligands bind to and inactivate PTCH1, derepressing SMO and promoting pathway activation2. 
The most promising targets of the pathway are the G-protein coupled receptor SMO, which 
transduces the Hh signal inside the cell, and the effector protein Gli1 which acts downstream 
of the SMO and promotes the transcription of Hh target genes. In the literature, some SMO 
antagonists have been described, some of which are currently under clinical investigation, 
whereas no records on the discovery of Gli1 antagonists are available3. The aim of this project 
is to discover and develop small organic molecules and/or natural compounds capable of 
inhibiting the Hh signaling pathway by antagonizing the SMO receptor and/or the Gli1 protein, 
thereby providing anticancer activity. According to molecular modeling studies the most 
promising compounds predicted by virtual screening will be tested in vitro on various cell-
based assays as, for example, in Hh-responsive cell lines and in stem/progenitor cells. The 
binding properties on the SMO receptor would be investigated by competition assays with 
Bodipy-cyclopamine, whereas the direct interaction with Gli1 could be studied by biophysical 
methods. Biological activity data will be used for refining computational models, while the 
most interesting active hits will be optimized through the rational design and synthesis. The 
most potent and less toxic compounds will be finally considered as the lead for further and in 
depth studies such as pre-clinical trials.  
 
                                      
[1] N. Engl. J. Med. 2009, 361, 1173;  
[2] Bioorg. Med. Chem. Lett. 2009, 19, 5576;  
[3] Cancer Sience 2011, 102, 1756; 
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Oligopeptides containing specific recognition unit (e.g. antibody or T-cell binding site, enzyme 
substrate) or possessing cell penetrating properties (e.g.oligoarginine, penetratin) are 
frequently utilized to target cell-surface or intracellular binding structures for delivering 
covalently attached entities (e.g. fluorophor, drug, enzyme modulators). Therefore the 
appropriate combination of conjugation strategies to merge two components without loosing 
their functional properties is important. Examples will demonstrate the application of different 
synthetic approaches for construction of oligopeptide conjugates with different partner 
molecules (e.g. antitumour drugs, like daunomycin, pemetrexed, ferrocene and vinblastin 
derivatives). The importance of isomerization during derivatization, the selection of the linkage 
between the components (thioether, disulphide, acid labile amide, etc.) will be discussed in 
the context of functional properties. The biomedicinal application of these bioconjugates as 
potential 22iological as well as diagnostic tools for identification novel biomarker in tumour, 
infection or metabolic diseases will be outlined. 
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P-glycoprotein (P-gp, a drug efflux pump) is often upregulated in cancer stem cells and in drug 
resistant cells. P-gp is usually localized in the cytoplasmic membrane but can also be found in 
the nuclear, mitochondria or in other intracellular membranes, indicating that it might be 
involved in intracellular mechanisms other than drug efflux (reviewed in Palmeira et al., Curr 
Med Chem 2012). We have also seen that P-gp may be transferred via microvesicles between 
drug-resistant and drug-sensitive cells (unpublished results), which confirms data from other 
researchers and indicates the influence of this protein in the drug resistant phenotype of 
tumour cells. 
Previous studies from our group have shown that by downregulating the expression of P-gp in 
a chronic myeloid leukaemia (CML) cell line which overexpresses P-gp (K562Dox), it was 
possible to increase cellular sensitivity to molecular targeted drugs such as Imatinib (Lima et 
al., Cancer Therapy, 2007). We have also proved that concomitant downregulation of P-gp and 
xIAP (an antiapoptotic protein) in a drug resistant cell line increased sensitivity to that drug 
(Seca et al., Hematology, 2011). In addition, given our interest in P-gp, we have started 
collaboration with CEQUIMED-UP and University of Madeira and we have worked towards 
identifying P-gp inhibitors (Palmeira et al., Curr Pharm Design, 2012) which would have 
concomitant antitumour activity. This collaborative work allowed to find some novel small-
molecules with dual activity (anti-Pgp activity and antitumour) (Palmeira et al., Biochem 
Pharmacol, 2012). Nevertheless, at least for some of them, modulation of the activity of other 
drug efflux pumps, such as MRP and BCRP, was also observed. In addition, interference with 
CYP34 which was predicted by in silico studies, was also confirmed in vitro (Palmeira et al., J 
Pharm Pharm Sci, 2012).  
These results indicated that some of these molecules may have potential as anticancer drugs. 
Indeed, we will present unpublished data which indicates that one of the synthesised 
molecules has a potent antitumour potential, inducing autophagy and apoptosis in melanoma 
and in non-small cell lung cancer (NSCLC) cell lines. Importantly, this small molecule was found 
not to be toxic to human lymphocytes (at the GI50 concentration determined for the tumour 
cell lines) and was shown to significantly reduce the growth of human NSCLC cancer cells in 
xenograph models in nude mice.  
These molecules may be of interest to target cancer stem cells, particularly in the cases with P-
gp overexpression. 
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Ecdysteroids are insect molting hormone analogs also present in several plant species 
including dietary ones such as spinach, where principal role of these compounds is apparently 
defensive against non-adapted herbivores. Ecdysteroid can also exert various beneficial 
metabolic effects in mammals via rather unclear mechanisms; non-hormonal anabolic activity 
of these compounds resulted in the marketing of a wide range of ecdysteroid containing food 
supplements worldwide. 
Protoflavones are oxidated flavonoid derivatives with an unusual non-aromatic B-ring. These 
flavonoids are potent anticancer agents both in vitro and in vivo: they were shown to promote 
oxidative stress and exert apoptosis in various cancer cell lines and tumor xenografts. Most 
recently, some of these compounds were found to inhibit ATR-dependent signaling, a crucial 
regulator of DNA-damage response. 
Structures of 20-hydroxyecdysone (20E), the most abundant phytoecdysteroid, and 
protoapigenone, a natural protoflavone are shown below. 
 
 
 
 
 
A brief summary is to be presented on our latest developments in these two topics. Our group 
has recently discovered, that less polar ecdysteroid derivatives such as for example 20E 
2,3;20,22-diacetonide, are potent modulators of the ABCB1 efflux pump mediated multi-drug 
resistance, while the classical, polar ecdysteroids rather increase resistance. Testing around 60 
compounds allowed us to conclude fundamental SAR. According to protoflavonoids, a set of 
around 33 derivatives have been prepared by semi- or totalsynthetic approach and tested 
against various cancer cell lines, including MDR ones. Compounds with a 6-methyl substitution 
were found to exert a mild yet statistically significant selectivity against a transfected mouse 
limphoma cell line expressing the human ABCB1 transporter, based on which SAR is currently 
being explored with different substituents at C-6. 
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Aquaporins (AQPs) belong to a highly conserved group of membrane proteins involved in the 
transport of water and small solutes such as glycerol through the plasma membranes of many 
cell types and with a variety of important physiological roles. Overexpression of cell membrane 
AQPs has been detected in in tumor cells of different origins, particularly aggressive tumors, 
being associated with tumor formation, angiogenesis, cell migration and proliferation, and 
suggesting that AQPs might be a novel target of diagnostic and prognostic value. 
We recently reported on the potent and selective inhibition of AQP3 permeability by a water-
soluble gold(III) coordination compound (Auphen), using human red blood cells as well as PC12 
cells transfected with either AQP1 or AQP3 [1]. Here we present the effect that this selective 
inhibitor produces on cell proliferation of cell lines that considerable express AQP3 and 
compare it with cells with low/or none AQP3 expression. Our results indicate a potential 
therapeutic effect of Auphen over tumorogenis in tissues with large expression of AQP3 as the 
skin, suggesting that epidermoid carcinomas and other skin cancer types could be susceptible 
to Auphen treatment. In addition, through molecular modeling and site-directed mutagenesis 
we were able to identify the cys40 residue as crucial for Auphen binding. 
In order to gain further insight into the basic structure-activity relationships, fundamental for 
the design of new AQP3 inhibitors, we investigated other gold-based compounds as possible 
AQP3 inhibitors. We describe here the selective and potent inhibitory effect (in the nanoM 
range) of a series of Au(III) complexes bearing nitrogen donor ligands on AQP3 which, together 
with their high water solubility, makes them suitable candidates for future in vivo studies. 
Since AQPs have been identified in stem cells [2], investigation on their expression and 
modulation would provide valuable insights into the knowledge of stem cell biology and 
technology. 
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Carbohydrates are present on the surface of any mammalian cell as well as in the extracellular 
matrix surrounding these cells. During the development of cells in their particular environment 
this composition of glycoconjugates changes dynamically, leading to a continuous turnover. 
The typical glycoconjugates presented by cells are glycolipids, glycoproteins and 
proteoglycans, which display a high degree of variability and heterogeneity. The malignancy of 
cells is always accompanied by changes of the carbohydrates presented on the surface as well 
as the carbohydrate binding capacity of surface proteins with lectin-like functions. This allows 
to characterize and to purify cells, including all types of stem cells, by binding to either lectins 
or to carbohydrates.  
There are a number of glycosylated stem cell markers, which are routinely detected by 
antibodies directed towards the protein part. We are interested in the glycosylation status of 
cancer stem cell markers and other glycoproteins in relation to the “stemness” of the 
particular tumor cells. The upregulated presence of α2,6-linked sialic acid in tumor cells leads 
to increased formation of metastases. On the molecular level enhanced α2,6-sialylation 
reduces the interaction with pro-apoptotic galectins as well as Fas and TNFR1.[1] It was shown 
that α2,3-sialylated N-glycans were present on the tumor stem cell marker CD133 of glioma-
initiating cells and that removal of sialic acid reduced the stability of the marker glycoprotein 
on the cell surface.[2] The presence of externally added heparin-like glycosaminoglycans was 
found to drive resting stem cells into particular differentiation pathways.[3] 
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A computational prediction of a binding free energy (∆Gbind) between an inhibitor and a sugar-
processing enzyme is often complicated by the presence of a transition metal ion at the active 
site of an enzyme. The accuracy of ∆Gbind depends on a correct assessment of interaction 
energy terms between the inhibitor and the transition metal ion as well as amino acid residues 
at the active site. We proposed 3D-QSAR model with interaction energy descriptors calculated 
at the quantum mechanics level (LIE-3D-DFT). Our novel methodology is based on 
decomposition of 3D-descriptors to small structural fragments. The 3D-QSAR model was built 
and tested for a library of human Golgi α-mannosidase II (hGMII) inhibitors. hGMII is 
a glycoside hydrolase (GH38) with zinc ion co-factor and is a target for inhibition of growth and 
metastasis of cancer cells. We found significantly improved predicted power of the LIE-3D-DFT 
model compared with empirical models based only on docking score or force field functions. 
Our LIE-3D-DFT model was able accurately to predict active compounds with an average error 
of 1.5 kcal/mol for ∆Gbind, and it satisfactorily separated potent inhibitors from non-active 
compounds. 
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The goal of our research is to uncover new cellular and molecular mechanisms governing the 
balance between self-renewal and differentiation of stem cells (SCs). The local 
microenvironment, or “SC niche”, holds the key to control this SC fate choice by providing a 
number of instructive cues such as cytokines and growth factors. Crucial for proper 
implementation of these signals is the capability of SCs to perceive them at the precise time 
point and with the right strength. Identifying the critical mediators of SC:microenvironment 
crosstalk is a basic topic in SC research as it can permit a high degree of control over SC state 
and fate. We have recently demonstrated that different SC types express a new cell surface 
marker: the heparan sulphate proteoglycan Glypican4. We have demonstrated that Glypican4, 
which acts as gatekeepers of environmental signals to modulate their perception by target 
cells, is specifically required to maintain the self-renewal of mouse embryonic and neural SCs. 
Mechanistically, Glypican4 regulates self-renewal of ES cells by modulating Wnt/b-catenin 
signalling activities. Thus, our findings establish that Glypican4 acts at the interface of extrinsic 
and intrinsic signal regulation to fine tune SC fate. Another issue we have tackled in these 
studies is the serious problem that embryonic or induced pluripotent SCs develop teratomas 
when transplanted to adult tissues. We found that it is possible to uncouple cell differentiation 
properties of pluripotent cells from tumorigenic potential by manipulating Glypican4 activity 
levels. In particular, pluripotent cells lacking Glypican4 lose their intrinsic tumorigenic 
properties after implantation into nude mice, while maintain the pluripotent differentiation 
program both in vitro and in vivo. Gene expression profile analysis has also revealed that loss-
of-Glypican4 activity leads to the over expression of tumour suppressor genes in embryonic 
SCs. As Glypican4 is a cell surface protein our findings identify Glypican4 as a suitable target for 
designing therapeutic strategies aiming at impairing the teratoma potential of pluripotent SCs 
and increasing their differentiation efficiency. Glypican4 is over-expressed in human cancers 
such as colon cancer and glioblastoma where cancer SCs have been described. Interestingly, 
signalling pathways active in normal SCs regulates the self-renewal and differentiation 
programs of cancer SCs. In collaboration with members of this cost action we are interested in 
assessing the expression profile of Glypican4 in different cancer SC types and in evaluating the 
possibility that Glypican4 modulation triggers cancer SC differentiation. We anticipate that 
Gpc4 could permit the development of new therapeutic strategies targeting cancer SCs and 
involving both cytotoxic and differentiation triggering agents.  
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Stem cells possess the potential to generate identical daughter stem cells as well as more 
restricted progenitor cells. Stem cells have much longer life span and high proliferative 
potential. Therefore they are more predisposed to accumulate genetic and epigenetic 
mutations. That is why cancer is considered as a disease of stem cells. 
The aim of our study was to assess miRNA expression of canine mammary cancer stem cells. 
Three canine mammary cancer cell lines (CMT-U27, CMT-U309 and P114) were stained using 
Anti-Sca1 (Stem cell antigen 1) antibodies. The FACS analysis showed 0,3-1%  of Sca1+ cells in 
each of the cell line. The cells were sorted (using FACS Aria II) as Sca1+ and Sca1- and subjected 
to further analysis of miRNA expression (using Agilent custom miRNA microarray). 
The analysis revealed that 189 of 323 miRNAs showed significantly increased expression in 
Sca1+ cells, whereas only 1 miRNA (miR-27a) showed significantly decreased expression. 
PANTER analysis revealed that miR-27a targeted genes are mainly involved in inflammation 
mediated by chemokine and cytokine signaling pathway, Wnt signaling pathway, GnRH 
receptor pathway and EGF receptor signaling pathway. 
These genes were mainly involved in metabolic process, cellular process, cell communication 
and developmental process. 
The results of our study showed significant epigenetic regulation of cancer stem cells transition 
to differentiated cancer cells. 
 
This work was supported by the grant no. NN308574940. 
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Although tumor heterogeneity has been described since the first description of cancer, only 
recently recognized, the subpopulation of cancer stem cells (CSCs) are recognized as the ones 
responsible for cancer progression. Similar to the tumors, perhaps even more pronounced, 
breast CSC destiny is highly dependent of thier niche, and their fate, activation or quiescence, 
is determined by microenvironment. Microenvironemt was shown be instructive to tumor cells 
by modulating their tumorigenicity. Another factor contributing to variations in cell reaction to 
(chemo)therapeutics is oxidative stress. Oxidative stress, a state of increased reactive oxygen 
species (ROS) production, affects all cell systems. ROS are very reactive therefore cusing 
numerous consequences, like genetic instability, one of the major characteristic of cancer, but 
also affecting lipids causing peroxidation. End products of lipid peroxidation are reactive 
aldehydes, among which, 4-hydroxy-2-nonenal (HNE), is involved in different signaling 
pathways influencing cell's fate (e.g., differentiation, proliferation or apoptosis). Here, we 
investigated the influence of collagen modified by HNE on SUM159 cell differentiation and 
involvement of Hedgehog pathways in observed changes in cell differentiation. 
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Many biological problems are amenable to comparative gain of function experimental 
approaches. Conventional approach by introducing expression vector at random integration 
sites are confounded by expression variation.  Besides in mouse embryonic stem cells, gene 
targeting by homologous recombination is not possible in most cell lines. We developed novel 
expression system based on conditional Tet-on regulation with selectable Cre/Lox cassette 
exchange in a single-copy integration vector.  We demonstrated method for generation of cell 
lines with highly efficient inducible cassette exchange target loci. This system can be introduce 
in cell lines despite of their origin, differentiation stage or proliferation ability. Our system is 
ideal for comparative gain of function studies, such as comparing phenotypic effects of various 
genes, or evaluating mutants of a given gene.  The conditional nature of the expression system 
facilitates work with genes with toxic phenotypes that would affect generation of stable cell 
lines.  The most important is to generate clonal cell line in which there is single inducible locus, 
which is expressed robustly, it is not silenced, and it is not leaky. In this presentation we will 
show successful generation of various inducible cell lines, including human embryonic stem 
cell line, and we will discuss the possibility of using our system for modifying various cancer 
cell lines.   
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Growth factors such as epidermal growth factor (EGF) and basic fibroblast growth factor (b-
FGF) promote cancer stem cell (CSC) proliferation in many solid tumours. EGF signalling is 
essential for formation and maintenance of colon CSCs while CSCs marker CD133 expression is 
upregulated in CRC tumors that have a hyperactivated Ras-Raf-MEK-ERK pathway and is 
related to mutations in K-Ras. Intrinsic and acquired resistance to EGFR Tyrosine Kinase 
Inhibitors (TKIs) is increasingly well-recognized and is epitomised by, (i) genetic and epigenetic 
variations of genes in the EGFR oncogenic cascade, (ii) critical downstream effectors 
RAS/RAF/MEK/ERK and PI3K/AKT/mTOR, (iii) parallel pathways, including VEGFR, (iv) 
expression of the EGFRvIII variant, deprived of the extracellular ligand binding domain and (v) 
nuclear translocation and constitutive activation of pEGFR. 
By employing label-free phosphoproteomics, an unprecedented tool in dissecting molecular 
mechanisms of combined therapies in clinical molecular oncology and defining biomarkers of 
efficacy, we have shown that sensitivity of cancer cells to TKI cannot always be predicted by 
the activation status of the target. Compromised sensitivity during CRC progression could be 
reverted by an “off-target” functional nutrient, γ-Tocotrienol. The combination of γ-
Tocotrienol with quinazoline-based TKIs has been effective for both EGFR+ve and EGFR-ve 
tumors despite K-Ras mutation status, thus offering therapeutic solutions for primary, 
metastatic and recurrent tumors. In fact, EGFR-pathway activation did not seem to be the 
main determinant in making our cell model sensitive to TKIs. Pathways and phosphoprotein 
clusters with emerging role in malignant transformation and progression such as the 
spliceosome cluster and the endocytosis pathways disclose novel therapeutic targets and 
associated biomarkers of response, disclosing new opportunities and challenges for synthetic 
chemistry in overcoming resistance in colon cancer stem cells. 
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Cancer cells with stem cell-like characteristics, also called cancer stem cells (CSCs), are thought 
to be instrumental in tumor initiation, progression and recurrence. Recent studies have shown 
that cells undergoing epithelial-mesenchymal transition (EMT), a step thought to be an early 
event in metastatic dissemination, share gene expression profiles with CSCs. Establishment 
and growth of disseminating tumor cells at the site of distant metastases is accompanied by 
their re-differentiation and the transition from a mesenchymal to a more epithelial phenotype 
(MET). We are studying the functional interplay between two related transcription factors, 
signal transducer and activator of transcription 5 (Stat5) and Stat3 in the genetic and 
epigenetic regulation of non-metastatic and metastatic breast cancer cells. Simultaneous 
activity of both Stats is observed in a high percentage of human luminal breast cancers. In both 
normal and malignant cells, Stat5 activity regulates cell proliferation, differentiation and 
survival. Stat5 activation in tumors is associated with favorable prognosis, due to a more 
differentiated phenotype, the expression of the estrogen receptor and response to 
antiestrogen therapy. During involution, i.e. the postlactational regression of the mammary 
gland, P-Stat3 regulates lysosomal-mediated cell death.  
To gain insights into the functions of Stat3 and Stat5 in oncogenesis, we established a mouse 
model which allows the investigation of genetic and epigenetic contributions to the initiation 
and progression of mammary tumors. In this model we used genetic manipulation of 
mammary stem cells (MaSCs) derived from primary tissue and the reconstitution of functional 
epithelium through transplantation into cleared fat pads to generate transgenic glands. The 
persistent activation of Stat5 during post-lactational involution resulted in the induction of 
non-metastatic adenocarcinomas, resembling human luminal-A breast cancer subtype. These 
tumors could be serially transplanted in BALB/c wild-type recipient mice and contain a small 
fraction of Lin-CD24lowCD44high tumor initiating cells. Both primary and secondary tumors 
show simultaneous activity of Stat5 and Stat3 and express estrogen and progesterone 
receptors (ER+PR+) and their downstream target genes like amphiregulin, RANKL and Wnt4. 
We performed microarray gene expression analysis of tumor tissues and P-Stat5 transgenic 
grafts to identify potential Stat target genes, which might be involved in Stat induced 
oncogenesis. We are also studying the contribution of Stat5 and Stat3 to the regulation of 
metastatic processes and regulation of EMT and MET. For this purpose we employ newly 
discovered specific inhibitors of these transcription factors. Our tumor model allows the 
identification of new genetic and epigenetic determinants in the etiology of breast cancer and 
metastasis formation, and the evaluation of the therapeutic potential of Stat3 and Stat5 
directed drugs. 
 
“c-Kit is required for growth and survival of the cells of origin of Braca1 mutation associated breast 
cancer” J. L. Regan, H. Kendrick, F.A. Magnay, V. Vafaizadeh, B. Groner, and Matthew J. Smalley, 
Oncogene 31, 869-83 (2012) 
“Stat5 assumes distinct functions in subsequent stages of mammary gland development and mammary 
tumor formation” V. Vafaizadeh, P. Klemmt and B. Groner, Frontiers in Bioscience 17, 1232-50 (2012) 
“TGFβ signaling serves dual purposes during the dissemination and metastasis formation of breast 
tumor cells” Vida Vafaizadeh, Ulrike Graab, Tahmineh Darvishi, Rita Salomé Gonçalves Machado and 
Bernd Groner Horm Mol Biol Clin Invest 10, 227–239 (2012)  
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The occurrence of resistance to anticancer agents is a major obstacle for successful cancer 
chemotherapy. The emergence of resistance to anticancer drugs, in particular multidrug 
resistance (MDR) has made many of the available anticancer drugs ineffective.1 MDR, is a 
complex multifactorial phenomenon that can result from a number of biochemical 
mechanisms. The enhanced activity of various members of the family of adenosine 
triphosphate binding cassette (ABC)-transporters was associated with different types of MDR.2. 
ABCB1, also known as P-glycoprotein, is a membrane protein member of the ATP-binding 
cassette (ABC) transporters superfamily. These membrane-embedded transport proteins 
decrease the intracellular drug accumulation, by and ATP-dependent efflux. This reduces the 
cytotoxicity of the anticancer agent and enables the tumour cells to survive. MDR problem 
could be overcome using potent and selective Pgp inhibitor.3 Since MDR is a major obstacle in 
clinical management of human cancers, it is important to design alternative therapy strategies 
that can be used in the treatment of drug-resistant phenotype. Until now, potential candidates 
failed clinical trials due to poor selectivity. The first generation of chemosensitizers where 
ineffective at non-toxic concentrations, while second generation chemosensitizers often failed 
because of simultaneous Pgp and CYP3A4 inhibition.4 jatrophane and lathyrane diterpene are a 
class of natural compounds, which were extracted from plants of the genus of Euphorbia. The 
phytopharmacological properties of the genus Euphorbia are well documented. A broad range 
of biological properties have been reported for constituents of the plant extract.5 In particular, 
jatrophane and lathyrane have been found to be potent and specific P-glycoprotein 
modulators. 
A scalable and solid synthesis of ring A is necessary in order to prepare a small library of 
jatrophane analogue. L-Sorbose, is a cheap and readily available natural sugar. Despite the 
similarity with the well exploited D-Fructose, only few methods were developed for the easy 
modification of this interesting sugar.6 Our results on this subject will be communicated. 
 
  
                                                           
1 Borowski, E.; BontempsGracz, M.; Piwkowska, A. Acta Biochim. Pol., 2005, 52, 609. 
2 Lage, H. Cell. Mol. Life. Sci. 2008, 65, 3145. 
3 (a) Robert, J.; Jarry, C. J. Med. Chem. 2003, 46, 4805. 
4 Choi, S. Cancer Cell Int. [Online] 2005, 5, 30. 
5 Hiller, K.; Melzig, M. F. Lexikon der Arzneipflanzen und Drogen; Spektrum Akademischer Verlag: 
Heidelberg, Germany, 1999. 
6 Zebiri. I., Balieu, S., Guilleret, A., Reynaud, R., Haudrechy, A. Eur. J. Org. Chem. 2011, 2905-2910 
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Our recent efforts to combine a pharmacophore responsible for thrombin inhibition and a 
pharmacophore common to fibrinogen receptor antagonists into a low molecular weight 
peptidomimetic compound resulted in a series of 1,4-benzoxazine and 1,4-benzodioxine 
compounds [1,2] which were identified as potent inhibitors of angiogenesis as revealed by 
inhibition of proliferation of four cell lines, inhibition of endothelial cell migration, inhibition of 
tube formation and CAM assay. Although thrombin inhibition remains the most probable 
explanation for their inhibition of angiogenesis, docking experiments and VEGFR2 kinase assay 
indicate that other targets such as VEGFR2 might be involved [1]. Their interaction with growth 
factor/receptor tyrosine kinase signaling pathways and antiangiogenic activity is a potential 
which might be exploited in targeting cancer stem cells. This avenue will be explored as part of 
COST Action CM1106 cooperation.  
________ 
 
[1]  M.Ilić, J.Ilaš,
 
 P.Dunkel, P. Mátyus, A.Boháč, S. Liekens and D.Kikelj: Novel 1,4-benzoxazine and 1,4-  
benzodioxine inhibitors of angiogenesis; Eur. J. Med. Chem 2012, 58, 160-170. 
[2]   M. Ilić, P.Dunkel, J.Ilaš, E. Chabielska,
 
A.Zakrzeska, P.Mátyus and D. Kikelj: Towards dual antithrom-
botic compounds – Balancing thrombin inhibitory and fibrinogen GPIIb/IIIa binding inhibitory 
activities of 2,3-dihydro-1,4-benzodioxine derivatives through regio- and stereoisomerism. Eur. J. 
Med. Chem 2013,in press; DOI: 10.1016/j.ejmech.2013.01.002.  
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The outcome for patients with advanced metastatic and recurrent prostate cancer is still poor. 
Therefore, new chemotherapeutics are required, especially for killing cancer stem cells that 
are thought to be responsible for disease recurrence. In this study, we screened the effect of a 
novel palladium-based anticancer agent (Pd complex) against six different prostate cancer cell 
lines, and primary cultures from seven Gleason 6/7 prostate cancer, three Gleason 8/9 
prostate cancer and four benign prostate hyperplasia patient samples, as well as cancer stem 
cells selected from primary cultures. MTT and ATP viability assays were used to assess cell 
growth and flow cytometry to assess cell cycle status. In addition, immunofluorescence was 
used to detect γH2AX nuclear foci, indicative of DNA damage, and Western blotting to assess 
the induction of apoptosis and autophagy. The Pd complex showed a powerful growth-
inhibitory effect against both cell lines and primary cultures. More importantly, it successfully 
reduced the viability of cancer stem cells as first reported in this study. The Pd complex 
induced DNA damage and differentially induced evidence of cell death as well as autophagy. In 
conclusion, this novel agent may be promising for use against the bulk of the tumour cell 
population as well as the prostate cancer stem cells, which are thought to be responsible for 
the resistance of metastatic prostate cancer to chemotherapy. Significantly, this study also 
indicates that the combined use of the Pd complex with an autophagy modulator may be a 
more promising approach to treat prostate cancer. 
 
  
39 
 
P9.  
Abl acts as a “signalling node” for maintenance, propagation, and 
motility of glioblastoma cells 
 
F. Lamballe1*, F. Conti1*, N. Baeza2, S. Richelme1, R. Dono1,  
D. Figarella-Branger2, and F. Maina1 
1
Aix-Marseille University – Developmental Biology Institute of Marseille-Luminy (IBDML) – 
CNRS UMR7288, Campus de Luminy, case 907, 13288 Marseille (France)  
2
Aix-Marseille University – Centre de Recherche en Oncologie et Oncopharmacologie – INSERM 
UMR911, 27, Bd Jean Moulin, 13385 Marseille (France) 
 
The fate and position of cells during nervous system development and adult neurogenesis is 
finely regulated by environmental signals. These signals in adult brain ensure maintenance of a 
pool of stem cells needed for normal brain physiology and for regeneration processes. 
Alteration of cell signalling response triggers pathological programs leading to tumorigenesis. 
The identification of key signalling mediators is crucial to maximize effectiveness of 
molecularly targeted anticancer therapies.  
We are interested to explore how the plasticity of cells during developmental and oncogenic 
processes allows them to respond and adapt to environmental signals. We found that the non-
receptor tyrosine kinase Abl is expressed and constitutively activated in different human 
glioblastoma (GBM) cells. This is consistent with previous studies showing that Abl is one over 
the 12 proteins discriminating high- versus low-grade gliomas. We hypothesized that Abl may 
integrates environmental outcomes by functioning as a “switch modulator”. Such “switch 
modulator” property of Abl is highlighted by a number of apparently contradicting results 
showing that Abl can act either as a signalling “inhibitor” or as a signalling “promoter” of a 
given biological response, depending on the cellular context and on the incoming 
environmental stimuli.  
We found that impairment of Abl signalling causes acquisition of mesenchymal-like 
characteristics, altering cell polarity and motility. Intriguingly, Abl inhibition interferes with 
tumour sphere formation and anchorage-independent growth of GBM cells in vitro. Xenograft 
experiments show that Abl inactivation suppresses the tumorigenic capacity of GBM cells in 
nude mice. We have performed biochemical and qRT-PCR studies to highlight the underlined 
molecular mechanism and found that Abl signalling inhibition provokes a drastic change in the 
activation of multiple pathways. We also found expression changes for genes related to 
epithelial and mesenchymal state (e.g. CDH1, Snail1), to stemness (e.g. CD133, nestin), and to 
the SHH pathway (e.g. SHH, SMO). Altogether, these biological and biochemical outcomes 
point to Abl as a “signalling node” that is capable of modulating the biological properties of 
GBM cells. Intriguingly, we found that Abl signalling modulates also self-renewal of human 
primary GBM stem cells. It has been shown that expansion and maintenance of Bcr-Abl 
positive leukemic stem cells is dependent on SHH pathway activation. Thus, it is tempting to 
speculate that Abl signalling impacts the maintenance of normal and cancer stem cells, 
possibly according to the environmental signals. 
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Ovarian cancer ranks fifth in both cancer incidence and mortality in Western women and has a 
high mortality rate. Despite the fact that more than 70% of the patients respond to front line 
therapy (surgery followed by a platinum based chemotherapy) most of them will eventually 
relapse and die from chemo-resistant disease. A number of evidence suggests that the cancer 
stem cell model also applies to ovarian tumor, even if no consensus on which markers define 
the ovarian cancer stem cell has reached yet. Among other CD133 and Aldehyde 
Dehydrogenase (ALDH) have been evocated as possible markers associated with ovarian 
cancer stem cells. The aim of the present work was to study the expression of these markers in 
9 stabilized ovarian cancer cell lines and in 108 fresh tumour ovarian samples. We found that 
among the total patients analyzed, 13% of them was completely negative for ALDH activity and 
26% was negative for CD133 staining. Similar data were obtained in cancer cell lines. Both 
markers were variably expressed within the samples and when both studied in the same tumor 
sample, no statistically significant correlation between ALDH enzymatic activity and CD133 
expression was found. No statistical significant correlation was found also between the 
percentage values of positive ALDH and CD133 cells and the number of serial passages 
patient’s cultures underwent, suggesting that these markers do not confer by themselves a 
self-renewal growth advantage to the cultures. In some cases, cells positive and negative for 
these markers were sorted and studied for their ability to grow in nude mice.  We correlated 
the expression of CD133 and ALDH in our patient cohort, but no correlation with response to 
therapy, progression free survival and overall survival was found, suggesting that neither ALDH 
enzymatic activity and CD133 expression provide additional predictive/prognostic information 
in ovarian cancer patients.  
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The development of novel drug delivery systems to enable and ensure improved pharmacokinetic 
and pharmadynamic profiles of medicines is of crucial importance in modern pharmacology and 
therapeutics. The use of ordered mesoporous carbons (OMCs) in drug delivery practices has 
received considerable attention due to the properties of these materials such as high-surface 
areas, uniformity, tunable pore sizes ranging from 3 to 10 nm, high degree of structural ordering, 
facile synthesis, high thermal, chemical and mechanical stability. To this end, mesoporous carbon 
materials (CMK-3) were synthesized and studied for their ability to incorporate poorly water 
soluble drugs. Namely, the non-steroidal anti-inflammatory drugs ibuprofen and indomethacin 
were encapsulated and further characterised by means of Differential Scanning Calorimetry 
(DSC), X-ray Powder Diffraction (XRPD), Fourier transform Infrared (FT-IR) and X-ray Photon 
Electron Spectroscopy (XPS). In both cases, drugs were in an amorphous state in the pores of 
the carbon carrier as being evident from the physicochemical characterisation studies. In 
particular, in acidic environment (pH 1.2) a faster release profile for indomethacin has been 
observed compared to ibuprofen formulation. Both formulations reached a plateau within 2 
hours. Based on these data, cytotoxicity assays were conducted on the Caco-2 cell culture 
model to further evaluate the pharmacological profile of CMK-3. Importantly, the material has 
exhibited no significant toxicity as observed by the kinetics of cell proliferation capacity and the 
assessment of cell death in culture. Moreover, uptake and subcellular localisation of the 
material was evident very early upon exposure of Caco-2 cells and further explored in a dose- 
and time-dependent manner through optical and fluorescence microscopy. Overall, the CMK-3 
material has shown promising technological and pharmacological profiles as a novel potential 
drug delivery system. 
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Many of tyrosine kinase inhibitors (TKI) are already involved in cancer treatment. There are 
some data in the recent literature that TKI are influencing also highly resistant tumor stem 
cells. There is substantial evidence that many human cancers are driven by a small 
subpopulation of cells that display stem cell properties. Cancer stem cells (CSC) are 
chemoresistant and implicated in tumor recurrence, metastasis and high patient mortality. 
Substances impairing CSC activity could be invaluable as novel cancer therapeutics. [1] 
Glioblastoma multiforme (GBM) including a small subpopulation of brain tumor stem-like cells 
(BTSC) are likely responsible for the therapy resistant and pervasive nature of GBM. Current 
therapies have only limited effect on targeting and eliminating BTSC. The current attempts to 
implement tyrosine kinase inhibitors (TKIs) as novel mechanism-based molecularly-targeting 
therapies against GBM have been reviewed recently. [2] The possible role of EGFR as a 
regulator of "stemness" was investigated in HNSCC cells. Activation of EGFR by the addition 
of EGF ligand resulted in the induction of CD44, BMI-1, Oct-4, NANOG, CXCR4, SDF-1 and 
increased tumorsphere formation, a characteristic ability of cancer stem cells. Conversely, 
treatment with the EGFR kinase inhibitor, Gefinitib (Iressa), resulted in decreased expression 
of the aforementioned genes, and loss of tumorsphere-forming ability. Cancer stem cells, 
when treated with Gefitinib, possessed a lower capacity to invade and became more sensitive 
to cisplatin-induced death in vitro. These results suggest that EGFR plays critical roles in the 
survival, maintenance, and function of cancer stem cells. Drugs that target EGFR might be an 
effective treatment for HNSCC. [3] The receptor tyrosine kinase (RTK) family mediates the 
multiple oncogenic growth factor receptor signaling and contributes to the pathogenesis of 
glioblastoma. The expression of stem cell marker in glioblastoma tissue has prognostic 
significance. Notch receptor expression is moderately upregulated and correlated with that of 
VEGFR2, VEGFR3, and PDGFRβ. [4] Bevacizumab (humanized VEGF antibody) inhibits brain 
CSC growth. Nimotuzumab, a monoclonal antibody against the epidermal growth factor 
receptor (EGFR), reduces CSC-like subpopulations in mouse models of brain tumors. [5] Anti-
angiogenesis agents and cancer stem-like cells (CSC) are opening new avenues for targeted 
cancer therapy. Endothelial cells are a key component of the CSC niche. One approach may 
be direct targeting of tumor endothelial cell fate could inhibit angiogenesis but also the self-
replication of CSC, which relies on signals from surrounding endothelial cells in the tumor 
microenvironment. The Notch pathway is central to controlling cell fate both during 
angiogenesis and in CSC from several tumors. [6] VEGFR2 is regarded as an endothelial cell 
protein, evidence suggests that VEGFRs may be expressed also by cancer cells. Glioblastoma 
multiforme (GBM) is characterized by florid vascularization and aberrantly elevated VEGF. 
Antiangiogenic therapy with bevacizumab reduces GBM tumor growth. VEGFR2 is 
preferentially expressed on the cell surface of the CD133+ human glioma stem-like cells 
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(GSCs), whose viability, self-renewal, and tumorigenicity rely, at least in part, on signaling 
through the VEGF-VEGFR2-Neuropilin-1 (NRP1) axis. A direct inhibition of VEGFR2 kinase 
may block the highly dynamic VEGF-VEGFR2-NRP1 pathway and inspire a GBM treatment 
strategy. [7] 
On the poster a development of new KDR inhibitor will be depicted. 
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Cancer stem cells (CSC) are defined as the tumorigenic subpopulation of cancer cells. CSC are 
resistant to current therapies, drive tumor post-therapy recurrence and are responsible for 
tumor seeding ability during metastatic spread. The receptor tyrosine kinase Axl is associated 
with metatstasis and poor overall survival in breast cancer. Axl is activated by epithelial-to- 
mesenchymal transition and correlates with markers of the CSC phenotype. Hence, targeting 
Axl may affect CSC activities in breast cancer. We assessed the effect of Axl inhibitors on CSC 
functions in in vitro and in vivo models systems. RNA intererfence, antibody and small 
molecule Axl kinase inhibitors effectively blocked CSC activity in in vitro mammosphere 
forming assays with breast cancer cells. Pretreatment with the chemotherapeutic docetaxel 
enriches chemoresistant CSC populations that form tumors when implanted subcutaneously 
into the flank of syngeneic Balb/C mice. Docetaxel and Axl inhibitor combination treatments 
blocked tumor initiation activity in vivo. These results suggest that Axl inhibitors can target CSC 
activity in breast cancer.     
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Breast cancer still represents leading cause of mortality and morbidity in women nevertheless 
of the great improvements in early diagnostics and cancer therapy made in the last few 
decades. Even though these improvements led to better understanding of the underlying 
molecular mechanisms, resistance to classical chemotherapeutics is still a tremendous 
challenge for breast cancer therapy. About 30% of all breast cancer patients who are 
successfully treated at early stages are suffering a relapse accompanied by metastasis and 
chemoresistance to classical drugs. Among the wide variety of drugs used in breast cancer 
chemotherapy treatments, doxorubicin is frequently used either as single-agent or in 
combination with other drugs. Since breast cancer is heterogeneous disease it can be 
categorised into three basic therapeutic groups: hormone (oestrogen (ER) and progesterone 
(PR)) positive with the best prognosis, HER2 positive and triple-negative(ER-, PR-, HER2-) with 
the worst prognosis. These subtypes were shown to respond differently to chemotherapy. On 
the other hand we must not neglect the role of the microenvironment, especially extracellular 
matrix (ECM) and its modifications, on the cancer treatment and its prevention or progression. 
Therefore we have investigated the effect of doxorubicin treatment and 4-hydroxynonenal-
modified microenvironment, in the 3 different breast cancer cell lines: MCF-7 (ER+, Pr+), SkBr3 
(Her2+) and SUM 159 (triple negative). Our results of cell proliferation and Intracellular 
reactive oxygen species (ROS) production have revealed difference in cell type responses. 
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Epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) are 
fundamental mechanisms controlling multiple events during embryonic development and 
cancer. Cancerous cells undergoing EMT, exhibit a mesenchymal-like phenotype with 
concomitant polarity loss, increased invasion and apoptosis resistance, which unable 
detachment from the primary environment. Nevertheless, the establishment of cancerous 
cells at novel locations is only possible for cells that are successful in undergoing the reverse 
process MET. Although EMT inducers and cellular outcomes have been largely studied, the 
molecular players and features of cells that revert through MET are far from being recognized.  
In the present work, we produced a dynamic EMT/MET model aiming at analyzing the whole 
transcriptome variation and defining the biological pathways that determine these transitions. 
We induced EMT/MET in a normal mouse mammary cell line (EpH4) by adding/removing TGF-
β1. DNAse treated total RNA extracted at distinct EMT/MET-timepoints was subjected to 
whole transcriptome sequencing (RNAseq). Bioinformatic analysis was performed using in 
house pipelines and commercially available software. Validation was performed using qRT-
PCR, Western Blot and immunofluorescence of selected differentially expressed targets.  
We confirmed the occurrence of EMT and MET by analysing the differential transcription of 
classical epithelial and mesenchymal markers. Bioinformatic analysis of RNAseq data 
uncovered thousands of genes differentially expressed in correlation with differential 
activation of several pathways. For example, and in addition to the TGF-β signalling pathway, 
we have observed differential activation of the Wnt-signalling pathway, BMP signalling 
pathway, Toll-like receptor-signalling pathway, Human Embryonic Stem Cell Pluripotency 
pathway, etc. We have also uncovered novel biological mechanisms underlying EMT/MET such 
as functional inactivation of E-cadherin by impaired glycosylation (1). In addition, the 
dynamicity of our EMT/MET model allowed us to uncover novel epigenetic mechanisms: for 
example, we explored the differential expression of a recently annotated differentiation-
related gene, Dies1, which became overexpressed in cells after undergoing MET in 
concomitance with its promoter demethylation.  
In conclusion, we were able to establish a dynamic in vitro model of EMT/MET, which allows 
uncovering and studying novel biological and genetic mechanisms using a non-biased genome 
wide approach. In addition, this model could also be used to test novel inhibitors designed 
specifically against the identified differentially expressed genes/pathways. 
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Presently, platinum-based coordination complexes are among the most widely used antitumor 
agents in the clinic .The effectiveness of cisplatin lies in its ability to covalently bind DNA, 
leading to important changes in the helical structure. In spite of the efficacy of platinum-based 
treatment regimens, long-term cure is difficult to obtain. The major drawbacks include a) 
severe and sometimes life-threatening toxic side effects; b) activation of drug resistance 
mechanisms by tumor cells; c) inadequate intratumor concentration of the drug and tumor 
microenvironmental interactions; d) relatively poor pharmacokinetic profiles and e) increased 
DNA repair capacity. As part of our program aimed to advance DNA as a drug target, we were 
interested in devising novel platinum containing dual compounds that interacted in an 
effective way with DNA and in addition accomplished the requirements of solubility in the 
body fluids and improved cellular uptake. In this context, a promising approach seemed to be 
the conjugation of platinum to analogues of the natural antitumor compound camptothecin 
(CPT).   
In this poster we report the design, modeling, synthesis and biological activity evaluation of 
new hybrid agents formed by CPT derivatives and diaminedichloro-platinum (II) complex. The 
compounds showed growth inhibitory activity against a panel of human tumor cell lines, 
including sublines resistant to topotecan and platinum compounds. The derivatives were 
active in all the tested cell lines, and the most active one was able to overcome cisplatin 
resistance in the osteosarcoma U2OS/Pt cell line. Platinum-containing camptothecins 
produced Platinum-DNA adducts and topoisomerase I-mediated DNA damage with cleavage 
pattern and persistence similar to SN38, the active principle of irinotecan. The results support 
the interpretation that the diaminedichloro-platinum (II) complex conjugated to a 
functionalized camptothecin resulted in a new class of effective antitumor compounds. 
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The medulloblastoma is the most frequent malignant brain tumor of childhood, it belongs to 
the group of embryonal neuroepithelial tumors and arise from stem cells or early progenitor 
cells in the cerebellum1. The Hedgehog pathway (Hh) is an essential embryonic signalling 
cascade that regulates stem-cell and progenitor-cell differentiation in multiple developmental 
processes. Smoothened homologue (SMO) is a transmembrane protein that activates the 
downstream Hedgehog signaling pathway. PTCH1 is an inhibitory cell-surface receptor that 
constitutively suppresses activation of the hedgehog pathway by inhibiting SMO. Hedgehog 
ligands bind to and inactivate PTCH1, derepressing SMO and promoting pathway activation2. 
The most promising targets of the pathway are the G-protein coupled receptor SMO, which 
transduces the Hh signal inside the cell, and the effector protein Gli1 which acts downstream 
of the SMO and promotes the transcription of Hh target genes. In the literature, some SMO 
antagonists have been described, some of which are currently under clinical investigation, 
whereas no records on the discovery of Gli1 antagonists are available3. The aim of this project 
is to discover and develop small organic molecules and/or natural compounds capable of 
inhibiting the Hh signaling pathway by antagonizing the SMO receptor and/or the Gli1 protein, 
thereby providing anticancer activity. According to molecular modeling studies the most 
promising compounds predicted by virtual screening will be tested in vitro on various cell-
based assays as, for example, in Hh-responsive cell lines and in stem/progenitor cells. The 
binding properties on the SMO receptor would be investigated by competition assays with 
Bodipy-cyclopamine, whereas the direct interaction with Gli1 could be studied by biophysical 
methods. Biological activity data will be used for refining computational models, while the 
most interesting active hits will be optimized through the rational design and synthesis. The 
most potent and less toxic compounds will be finally considered as the lead for further and in 
depth studies such as pre-clinical trials.  
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EGCG [(−)epigallocatechin-3-gallate], a green tea-derived polyphenol, has been shown to 
suppress cancer cell proliferation, and interfere with the several signaling pathways and induce 
apoptosis. EGCG was reported to cause cell-cycle arrest in various mouse, rat and human cell 
lines through regulation of cell-cycle related oncogenes and proteins, particular cyclin D1 and 
its cyclin-dependent kinases (cdk4 and cdk6). 
The present investigation was designed to characterize the effects of EGCG alone and its 
combination with retinoic acid on NB4 cell growth and apoptosis. In this work it was found out 
that natural DNA methyltransferases inhibitor EGCG reduces cell proliferation, increases cell 
death – apoptosis and decreases the level of DNA methyltransferases gene expression 
(DNMT3a, 3b) in NB4 leukemia cells.  
NB4 cells were treated with 40 µM EGCG alone, in combination with 1 µM RA or with 1 µM RA 
alone. EGCG significantly inhibited the growth of NB4 cells at 40 µM concentration alone or in 
combination with 1 µM RA in a time-dependent manner. To examine the differentiating 
activity of EGCG we evaluate expression of the early differentiation marker CD11b in treated 
NB4 cells. EGCG alone did not affect differentiation of NB4 cells, but increased proportion of 
cells in the subG1 phase (undergoing apoptosis) up to 17% at 24 h and double augmentation at 
48 h (42%).  
For cell cycle analysis, NB4 cells were treated with 40 µM EGCG or 1 µM RA alone and in 
combination (1 µM RA and 40 µM EGCG) for 72 h. Cell populations in cell cycle phases were 
determined by flow cytometry. There was no additive effect on cell accumulation in the phases 
at 24-h treatments with EGCG or its combination with RA. Cell cycle analysis revealed that 
EGCG caused a decrease in the proportion of NB4 cells in the  S (12 %) and G2/M (9.2%) and an 
increase in the G0/G1 phase at 72 h point up to 78%, compared with control (non treated) 
cells. The combination treatment with EGCG and RA for 72 h caused an increase in the G0/G1 
phase up to 85% and decrease in the S (10%) and G2/M (5%) phases.  
To evaluate the changes in global methylation status after treatment of NB4 cells with EGCG, 
we labeled control NB4 cells and cells treated with 40 µM EGCG for 72 h with anti-5-Methyl 
Cytosine antibody and prepared flow cytometry analysis. We detected that EGCG alone 
decreased global methylation level in NB4 cells.  
In this study we examined the DNMT1 and DNMT3a, 3b gene expression in 40 µM EGCG-
treated NB4 cells undergoing apoptosis or RA-treated cells undergoing growth inhibition. The 
results showed that EGCG alone or in combination with RA slightly decreased the expression of 
DNMT3a gene in NB4 cells, but had no effect on DNMT1 and DNMT3b gene expression.  
To sum up, these results show that DNMT inhibitor EGCG is able to restore important functions 
of the cell by remodeling epigenetic changes and could be a potential agent in cancer 
treatment.  
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Ecdysteroids, herbal analogs of the insect molting hormone, have several beneficial effects in 
mammals among which is a mild anabolic effect with no interference with their steroid 
hormonal system. In our recent studies on over 60 ecdysteroids, some of these compounds 
were found to modulate ABCB1 transporter mediated resistance to doxorubicin. Moreover, 
Structure activity relationship (SAR) studies showed that apolar ecdsyteroids were more 
effective: for example, ecdysteroid diacetonides such as 20-hydroxyecdysone 2,3;20,22-
diacetonide (1) presented strong synergism with doxorubicin. 
In order to investigate the role of the substituents on the dioxalane rings at positions 2,3 and 
20,22, new compounds have been synthetized from the plant derived 20-hydroxyecdysone. 
For that purpose formation of dioxalane rings was achieved using different reagents, such as 
methyl-ethyl ketone, butyraldehyde. valeraldehyde or 3-pentanone, resulting in over 10 new 
compounds. Moreover, three further diacetonide derivatives of other natural ecdysteroids 
were obtained as side-products of the scale-up synthesis of 1. 
The compounds were tested for their capacity to modulate efflux mediated by the ABCB1 
transporter following the intracellular accumulation of the dye rhodamine 123, using flow 
cytometry, in L5178 mouse T-cell lymphoma cell line (non MDR) and its sub-cell line 
transfected with pHa MDR1/A retrovirus, overexpressing the human ABCB1 efflux pump (MDR 
cell line). The same MDR cell line was used to test the capacity of the compounds to modulate 
resistance of the cells to doxorubicin. These combination studies were done using the 
checkerboard microplate method and the MTT colorimetric assay, and the results were 
evaluated by using the CompuSyn software. 
The activity of the compounds formed using methyl-ethyl ketone studied is in accordance with 
the previous SAR studies, with synergistic activity comparable to that of compound 1, with 
exception to one that contained only a methyl group as substituent of the 2,3 dioxalane ring. 
Activity studies on several other compounds, as well as further extensions of the SAR study, 
are still in progress. 
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MUC1, a membrane-associated glycoprotein, is overexpressed in more than 80% of pancreatic 
tumors being correlated with carcinogenesis and poor prognosis. MUC1 participates in several 
oncogenic signaling pathways and was recently reported as being involved in resistance to 
standard chemotherapeutic agents and as a relevant marker of pluripotency in human 
embryonic stem cells. Recent studies revealed that a subpopulation of tumor cells with the 
potential to self-renew and differentiate - Cancer Stem Cells (CSC) - is responsible for initiation, 
progression, metastization and tumor recurrence. 
The objective of this study was to investigate the possible involvement of MUC1 in CSC biology 
in pancreatic cancer, one of the most fatal neoplasias. 
We investigated MUC1 expression in pancreatic CSC and we characterized MUC1 involvement 
in oncogenic signaling pathways of CSC.  
We isolated subpopulations of putative cancer stem cells from pancreatic cancer cell line HPAF 
II using a stem cell surface marker CD133 (prominin-I) and assessed the tumorigenic potential 
of this small subpopulation, MUC1 expression levels and possible alterations in associated 
oncogenic signaling pathways.   
The present work shows that pancreatic CSCs have a different expression profile regarding 
MUC1 and associated signaling partners. MUC1 seems to be a relevant player in pancreatic 
CSC biology that can contribute to the tumorigenic potential of this subpopulation and thus 
might constitute an elective target for alternative therapeutic strategies. 
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The homeobox transcription factor CDX2 plays a crucial role in intestinal cell fate specification, 
both during normal development and in tumorigenic processes involving intestinal 
reprogramming. The CDX2 regulatory network is intricate but it has not yet been fully 
uncovered. Through genome-wide screening of a three-dimensional culture system, the RNA-
binding protein MEX3A was identified as putatively involved in CDX2 regulation, so its 
biological relevance was addressed by setting up cell-based assays together with expression 
studies in murine intestine. We demonstrate here that MEX3A has a translational repressive 
function by controlling CDX2 levels in gastric and colorectal cellular models. This is dependent 
on the interaction with a specific binding determinant present in CDX2 mRNA 3`untranslated 
region. We have further determined that MEX3A impairs intestinal differentiation and cellular 
polarization, affects cell cycle progression and promotes increased expression of intestinal 
stem cell markers, namely LGR5, BMI1 and MSI1. Finally, we show that MEX3A is expressed in 
mouse intestine, supporting an in vivo context for interaction with CDX2 and modulation of 
stem cell properties. Therefore, we describe a novel CDX2 post-transcriptional regulatory 
mechanism, through the RNA-binding protein MEX3A, with a major impact in intestinal 
differentiation, polarity and stemness, likely contributing to intestinal homeostasis and 
carcinogenesis.  
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Retinoids, a large family of natural and synthetic compounds structurally related to vitamin A, 
play an important role in a variety of biological functions including vision, development, 
reproduction and cell differentiation and have been applied successfully to the management of 
severe skin disorders and more recently to cancer prevention and therapy.1  Retinoid 
signaling pathways, mainly induced by all-trans retinoic acid (ATRA), are involved in numerous 
processes in cells, particularly those mediating differentiation and apoptosis. Retinoids exert 
their effects through their interaction with the nuclear retinoic acid receptors (RARs) and 
retinoid X receptors (RXRs), which act as ligand-activated transcription regulators for specific 
genes.2 Moreover, ATRA concentration in the cytoplasm is very important for the cell as 
shortage or excess of causing malfunctions of the retinoid-mediated signaling pathways and is 
controlled by the so-called cellular retinoid-binding proteins. These proteins, CRABP I and 
CRABP II enhance the metabolism of ATRA to inactive derivatives3 or mediate channeling of 
ATRA from the binding protein to its receptors, respectively.2 
Strategies to induce cancer cell differentiation have been applied to select malignancies. ATRA 
is the most common differentiating agent in clinical practice and has been successfully used to 
treat acute promyelocytic leukemia, a stem cell malignancy. Like somatic stem cells, cancer 
stem cells (CSCs) exhibit self-renewal capacity and differentiation potential, albeit an aberrant 
and incomplete differentiation potential. Since the initial isolation of CSCs in leukemia, their 
existence in a wide variety of other cancers has been successfully demonstrated. It is necessary 
to understand mechanisms, by which differentiating agents influence tumor-initiating CSCs. 
Ying et al. have investigated the cellular and molecular responses of glioblastoma stem-like 
cells to ATRA. From several studies aiming to reveal the cellular mechanism for this response, 
it appeared that Notch signaling was the most prominent of these ATRA-responsive pathways.1 
Structurally, retinoids incorporate a lipophilic part (aromatic or non-aromatic), which is 
connected to a carboxylic group (the hydrophilic part of the retinoid) through a conjugated 
tetraene chain (Fig. 1). In an effort to improve the therapeutic index of this compound and its 
selectivity towards several biological targets, a variety of ATRA or acitretin (ACI)4  analogs have 
been synthesized from our research group. Acitretin in particular, a second generation 
monoaromatic retinoid, is the drug of choice for the systemic treatment of certain types of 
psoriasis.1 The mechanism by which acitretin acts seems not to be through binding with the 
retinoid receptors (it has low affinity for RARs) but through the displacement of ATRA from 
CRABPs (it has high affinity for CRABPs) and therefore by increasing the ATRA occupancy of the 
nuclear receptors.5 
We have synthesized a series of ACI analogs (II), suitable for structure activity relationship 
studies, and studied initially their potential antiproliferative activity against breast cancer MCF-
7 cells. These analogs were designed to present variable electron density, lipophilicity and 
steric bulk in the aromatic ring as well as variable dihedral angle between the aromatic ring 
and the spacer.4a 
These analogs were readily obtained using commercially available aromatic aldehydes and 
55 
 
methyl ketones (I), as starting materials, and linear or convergent method-logies and the 
Wittig or the Horner-Wadsworth-Emmons reaction for the assembly of the polyene chain. Key-
building blocks in the assembly of the tetraene chain were the phosphonate ester E-1, the E-
aldehyde 2, the E,E-aldehyde 3 and the E,E,E-aldehyde-4, all prepared stereoselectively 
through new methodologies, using hydroxyacetone as starting material. 
Given ATRA’s importance in the differentiation of CSCs and the library of our synthetic 
molecules we are currently interested to study (through collaboration with other StemChem 
members) the differentiation-inducing effect of these acitretin-type retinoids on CSCs, in order 
to discover and/or develop novel CSC regulators based on retinoids. 
 
 
 
[1]. a) For the most recent general monograph, see: M.B. Sporn, A.B. Roberts, D.S. Goodman, The 
Retinoids: Biology, Chemistry and Medicine, second ed. Raven Press, New York, 1994; b) L. J. Gudas; J. A. 
Wagner, J. Cell. Physiol. 2011, 226, 322. 
[2].a) V.C.O. Njar et al.  Bioorg. Med. Chem. 2006, 14, 4323 and references therein; b)  B.N. Chaudhuri, 
et al. Acta Cryst. D 1999, 55, 1850 and references therein. 
[3]. a) A. I. Lukaszewicz et al. J. Med. Chem. 2010, 53, 3439; b) M. Zhang; J. M. Rosen, Curr. Opin. Genet. 
Dev. 2006, 16, 60;  
c) M. Dean et al. Nature Reviews Cancer 2005, 5, 275; d) M. Ying et al. Oncogene, 2011, 30, 3454. 
[4]. a) G. E. Magoulas et al. Eur. J. Med. Chem. 2011, 46 , 721; b) D. Vourtsis et al. Eur. J. Pharmacol. 
2013,  698, 122. 
[5]. a) E. Hsia et al. J. Inv. Dermatol. 2008, 128 (2008) 125e130; b) K. Tian et al.,Biochemistry 1997, 36, 
5669. 
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Tumour drug resistance is a major issue in the management of cancer patients. It is currently 
believed that a small sub-population of tumour cells, evidencing stem-like properties (cancer 
stem-like cells - CSLCs), are partially responsible for tumour drug resistance. The study of this 
sub-population of cells is therefore extremely important as it may lead to the identification of 
potential therapeutic targets to improve cancer therapy and patient survival. 
Attempting to mimic in vitro the enrichment of CSLCs following chemotherapy that may occur 
in cancer patients, we have incubated lung and pancreatic cancer cell lines with 
chemotherapeutic agents at sub-lethal concentrations and studied the resulting cell 
phenotype alterations.  
Lung (NCI-H460, A549) and pancreatic (S2013) cancer cell lines were incubated with cisplatin 
or doxorubicin followed by a drug-free recovery period. Drug treatment led to a transient 
alteration in cell morphology in lung cancer cell lines, whereby cells acquired a more 
mesenchymal-like structure. In NCI-H460 cells, cisplatin exposure led to increased resistance 
towards the selecting drug but also to doxorubicin and gemcitabine. Enrichment of cells 
expressing the putative stem cell marker ABCG2, and to a much lesser extent CD133, was also 
observed. Increased expression of the apoptosis-related proteins Bcl-XL and XIAP and of the 
drug efflux pump P-glycoprotein was verified in the cisplatin-selected population, when 
compared to the parental NCI-H460 cell line. In the pancreatic cancer cell line (S2013), cisplatin 
or doxorubicin treatment led to a significant enrichment of cells expressing the stem cell 
marker CD133. However, only the population of cisplatin-enriched S2013 cells had increased 
drug resistance when compared to the parental cell line, possibly due to the verified 
overexpression of anti-apoptotic Bcl2 protein.  
The approach of incubating cells with sub-lethal doses of chemotherapeutic drugs has, so far, 
led to a verified enrichment in cells expressing cancer stem cell markers (CD133 and ABCG2) 
and possessing increased drug-resistance, possibly due to the overexpression of genes 
involved in drug efflux and apoptosis. Therefore, this approach could serve as an additional 
method to enrich for cancer stem like cells, and to identify, and later validate (e.g. by siRNA), 
molecular targets for overcoming chemoresistance in these cells. 
 
Acknowledgments: To FCT and COMPETE/QREN/UE-project (PTDC/EBB-BIO/099672/2008) for financial 
support. Salary support to GMA from POPH-QREN/Type 4.2, European Social Fund and Portuguese 
Ministry of Science and Technology (MCTES).  
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First step towards developing a targeted therapy for any diseases is to generate model system 
for studding the mechanism and for testing various therapeutic approaches. 
Fascioscapulohumeral muscular dystrophy (FSHD) is diseases which rather affect muscle stem 
cells then mature myofibers. Most likely the pathological effect is in prenatal and postnatal 
stage, during muscle formation and muscle regeneration. To address the both stages we 
engineered various stem cell line suitable to study gain of function during early embryogenesis 
(human and mouse ES cells) and myogenesis in adults (C2C12). In the cell lines we introduced a 
single gene, DUX4, which is believed to trigger the molecular cascade of FSHD pathology. We 
toke the advantage of conditional cell toxicity of DUX4 and we developed a small molecule 
screening platform for identifying inhibitors of DUX4. Assay based on rapid cell death within 24 
hours induced by high levels of DUX4 was used for high throughput screen of 44,000 
chemicals. The assay was proved to be easy control by titration of doxycyline, adaptable to 
miniaturized formats, robust, rapid, with low false positive rates and high signal to noise ratios.  
We identified more than 1280 compounds with significant rescue ability. To narrow down to 
direct DUX4 inhibitors, we have conducted serial follow up assays, including secondary screens 
to eliminate compounds which interfere with the rtTA/TRE inducible gene expression system, 
to distinguish common anti oxidants and/or anti stressors, to confirm reversion of toxicity in 
different non myogenic cell types. Several classes of compounds reverted toxicity indirectly, 
including antioxidants.  
By developing HTS platform and established cell based systems for follow up studies we 
established the base for the most crucial topic and urgent needs of FSHD patients: specific and 
direct pharmacological therapy. 
 
 
  
58 
 
P8.  
Anti-metastatic and anti-angiogenic properties of potential new anti-
cancer drugs based on metal complexes of selenosemicarbazones 
 
Dušan Sladića, Katarina Anđelkovića, Tamara Todorovića, Nenad Filipovićb, Dragana 
Mitića, Manja Zecc, Siniša Radulovićc 
a
University of Belgrade – Faculty of Chemistry, Studentski trg 12-16, 11000 Belgrade, Serbia; 
b
University of Belgrade – Faculty of Agriculture, Nemanjina 6, 11000 Belgrade, Serbia;
 c
National 
Cancer Research Center, Dept. of Experimental Pharmacology, Pasterova 14, 11000 Belgrade, 
Serbia.  
E-mail: dsladic@chem.bg.ac.rs (D. Sladić) 
 
Matrix metalloproteinases 2 and 9 (MMP-2 and MMP-9) are reliable markers of tumor cell 
invasion and migration potential. Malignant tumors are characterized by the increased matrix 
metalloproteinases expression compared to benign tumor, causing more effective degradation 
of the extracellular matrix resulting in increased invasion and migration of tumor cells. Metal 
complexes with 2-formylpyridine selenosemicarbazone (Scheme 1) significantly decreased the 
proteolytic activity of MMP-2 and MMP-9 in metastatic MDA-MB-361 (human breast cancer) 
cell line. The ligand, Zn(II) and Ni(II) complexes caused a slight decrease of MMP-2 protein 
secretion and activity in HeLa (human cervix carcinoma) cells, while a significant increase of 
levels of MMP-2 and MMP-9 secretion and activity was observed upon action of Cd(II) complex 
or cisplatin on the same cell line. In malignant cells, the complexes inhibited intracellular 
accumulation of reactive oxygen species, known for pro-angiogenic properties via VEGF 
(Vascular Enothelial Growth Factor) signaling, but no reduction in total cellular amount of 
VEGF was found. Also, tubulogenesis test showed anti-angiogenic effect of the complexes in 
treated endothelial cells. The data indicate that the complexes might have multiple 
mechanisms of angiogenesis inhibition. In addition, they could modulate metastatic phenotype 
of tumor cells. Our study provides experimental evidence that metal complexes with 2-
formylpyridine selenosemicarbazone inhibited tumor invasion, human vascular endothelial 
cells migration and tube formation. Ni(II) complex revealed to be the most potent.  
 
 
 
 
Scheme 1. 
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Signaling pathways, such as the Hedgehog (Hh) pathway, hold the key for unlocking the 
potential applications of stem cells and are also considered attractive targets for anti-cancer 
intervention.1 Although, several small molecule Hh inhibitors are undergoing clinical trials, 
there is a need to identify new inhibitors capable of overcoming acquired resistance.2 In this 
context, a natural product, Taepeenin D, has been recently identified to interfere with Gli 
function, which is the last step in Hh signaling.3 
 
 
Several analogues of Taepeenin D have been targeted for synthesis in order to: 
i) Establish Structure-Activity-Relationships for Taepeenin D, and 
ii) Pave the way for a total synthesis of the natural product itself. 
 
Their preparation, starting from the readily available Abietic acid, will be presented. 
Collaboration with other members of this Action is sought in order to evaluate the biological 
activity of the compounds prepared. 
 
 
Acknowledgments. This work is part of COST Action CM1106. 
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Triptolide 1 is a bioactive ingredient in traditional Chinese medicine that exhibits diverse 
biological properties, including anticancer properties1,2  One hydrosoluble derivative , 
minnelide as been recently developped as a drug against tumor cells in pancreatic cancer.3 The 
recent identification of GD2 (a glycosphingolipid) as a marker for breast CSCs has opened a 
way towards the inhibition of CSC-associated tumor growth, chemotherapy resistance and 
tumor metastasis.4 GD3S expression is critical for the expression of GD2, and suppression of its 
biosynthesis using triptolide against GD3S hampered mammosphere formation and tumor 
initiation.2  Furthermore as GD2 is an immune suppressant, it would be needed by cancer stem 
cells to counter immune cells during metastases and inhibition of GD2 expression in cancer 
cells may enhance the inherent ability of immune cells to kill cancer cells.  
In this context we have developed a straightforward access to an enantiopur triptolide 
precursor 2 as well as structurally closed analogues (R=alkyls, carbinols, X= O, N, C) using a 
diastereoselective Diels-Alder cycloaddition of an enantiomerically pure sulfinylquinone5 and  
highly functionalized semicyclic dienes.6  
 
 
1) Stefano Giustino Manzo, Zhao-Li Zhou, Ying-Qing Wang, Jessica Marinello, Jin-Xue He, Yuan-
Chao Li, Jian Ding, Giovanni Capranico, and Ze-Hong Miao Cancer Res, 2012 72:5363-5373 
2) Venkata Lokesh Battula, Yuexi Shi, Kurt W. Evans, Rui-Yu Wan, Erika L. Spaeth, Rodrigo O. 
Jacamo, Rudy Guerra, Aysegul A. Sahin, Frank C. Marini, Gabriel Hortobagyi, Sendurai A. Mani 
and Michael Andreeff
 
J Clin Invest. 2012;122(6):2066–2078 
3) Pr. Ashok.K.Saluja University of Minnesota, Masonic Cancer center 
4) Kwon HY, Kim SJ, Kim CH, Son SW, Kim KS, Lee JH, Do SI, Lee YC. Exp Mol Med. 2010;42(12):849-
55. 
5) M; Carmen Carreno, José L. Garcia-Ruano, Miguel A. Toledo Chem. Eur. J. 2000, 6, 288-291. 
6) a) Don Antoine Lanfranchi, Christophe Bour, and Gilles Hanquet . Eur. J. Org. Chem. 2011, 2818-
2826. b) Don Antoine Lanfranchi, Christophe Bour, and Gilles Hanquet . Eur. J. Org. Chem. 2010, 
5232-5247.   
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The development of new antineoplastic drugs remains a key to progress in cancer treatment. 
Nowadays, it is widely accepted that in the finding of new biologically active compounds it is 
essential the use of suitable screening methodologies that can address the mechanism of 
action at early stages of drug discovery. In addition, identifying the correct target of new 
bioactive molecules is critical to prevent further drug failures. In the scenario of drug 
discovery, numerous in vitro testing initiatives had been established. Thus far, no general 
methodology is established and literature on this hot topic is scarce. In this context, we 
proposed a strategy based in a Phenotypic Drug Discovery (PDD) approach [1]. Within our 
program directed at the discovery of new antitumor agents, we have drawn our attention to 
compounds that disturb the cell cycle. Our strategy relies on the use of a set of biological 
experiments organized in a modular fashion. 
Herein, we exemplified this strategy with a family of propargylic enol ether derivatives [2]. The 
study of the antiproliferative activity allowed us to define a structure-activity relationship 
(SAR), being DTA0100 identified as the lead compound. The stereochemistry of DTA0100 is not 
a critical factor for its biological activity. At a cellular level, DTA0100 induces cellular 
morphological changes such as the occurrence of multinucleated cells as a consequence of a 
prolonged mitotic arrest. At a cell signaling pathway level, DTA0100 induces the activation of 
the mitotic spindle checkpoint. At a protein level, DTA0100 produces a significant reduction of 
the polymer mass of microtubules affecting the spindle pole formation. We have identified 
tubulin as the main molecular target of DTA0100. The interaction between DTA0100 and 
tubulin is located at or near the colchicine binding domain. DTA0100 behaves as a microtubule 
destabilizing agent. 
Using different assays in sequential stages and in stepwise manner, our studies allowed us to 
understand the bioactivity of this family of compounds and led us to identify tubulin as the 
main molecular target. This discovery has been carried out using both cell free conditions and 
living cells. The rational use of chemical techniques in synergy with biological methods in this 
study led us to understand the bioactivity at the cellular level of a lead selected form a small 
library of compounds. Moreover, both areas are the foundation that provides a robust and 
reliable methodology for the identification of target candidates. In this context, bioactive small 
molecules can be effectively discovered by using a modular approach based on phenotypic 
changes induced by new chemical entities. 
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A novel ligand 2,6-diacetylpyridine bis(selenosemicarbazone) was synthesized and coordinated 
with Zn(II), Cd(II) and Ni(II). With Zn(II) and Cd(II), the ligand in dianionic form was coordinated 
as a quinquedentate in a trigonal bipyramidal geometry. With Ni(II) during coordination the 
ligand underwent elimination of hydrogen selenide and the product was coordinated as a 
quadridentate forming a square planar complex, the structure of which was determined by X-
ray analysis. The antioxidant activity of the compounds was found to decrease in the order: Cd-
complex > Zn-complex > Ni-complex > ligand. The cytotoxic activity of the synthesized 
compounds was performed on the panel of nine cell lines, including seven tumor cell lines 
(lung cancer A549, epithelial breast cancer MDA-MB-361, MDA-453, as well as highly 
metastatic breast cancer MCF-7 cell line, cervical cancer HeLa, melanoma cells FemX, and 
colorectal cancer cells LS) and two normal (endothelial EA.hy 926 and lung fibroblast MRC-5) 
cell lines. Cells were treated with the ligand, the complexes, corresponding salts, and cisplatin 
as a reference compound for 24 h. Cd complex was active to all cell lines, the most susceptible 
being FemX melanoma cells with IC50 of 1.58 µM. Zn complex was moderately active to almost 
all cell lines while Ni complex was inactive. 
 
 
Acknowledgments. This work was supported by the grant (OI 172055) from Ministry of Education, 
Science and Technological Development of the Republic of Serbia. 
 
  
63 
 
P13. 
Targeting the wt p53: synthesis of a new family of modulators 
 
Nuno A. L. Pereira, Ângelo Monteiro and Maria M. M. Santos 
Research Institute for Medicines and Pharmaceutical Sciences (iMed.UL) Faculty of Pharmacy, 
University of Lisbon, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal 
 
 
Apoptosis is a tightly regulated multi-step pathway that is responsible for cell death not only 
during development, but also in adult multicellular organisms, in which it partly controls cell 
numbers. Deregulation of apoptosis can result in severe pathological syndromes. For example, 
cancer can be caused in part by a prolonged lifespan of transformed cells that would be 
normally eliminated. In the last years our research group has been involved in the design and 
synthesis of new small molecules that act as apoptosis modulators (Figure) [1-4].  
In particular, more recently, we became interested in the synthesis of p53 family modulators. 
In fact, in half of all human cancers, the wild-type p53 tumour suppression protein is 
inactivated due to the overexpression of endogenous negative regulators such as MDM2. As a 
consequence, inhibiting the p53-MDM2 protein-protein interaction to reactivate the p53 
function represents a promising pharmacological approach for treatment of these cancers. 
Herein, our recent results on the synthesis of a library of potential new p53 modulators will be 
disclosed. 
 
Figure – Libraries of small molecules synthesized at Santos’s group. 
 
 
Acknowledgments 
This work was supported by Fundação para a Ciência e Tecnologia (Portugal) through project PTDC/QUI-
QUI/111664/2009, and FEDER funds through the COMPETE program under the project FCOMP-01-124-
FEDER-015752 (PTDC/SAU-FAR/110848/2009).  
 
References 
1. Glória, P. M. C.; Coutinho, I.; Gonçalves, L. M.; Baptista, C.; Soares, J.; Newton, A. S.; Moreira, R.; 
Saraiva, L.; Santos, M. M. M. “Aspartic vinyl sulfones: inhibitors of a caspase-3-dependent pathway”, Eur. 
J. Med. Chem. 2011, 46, 2141. 
2. Ribeiro, C. J. A.; Kumar, S. P.; Moreira, R.; Santos, M. M. M. “Efficient synthesis of spiroisoxazoline 
oxindoles”, Tetrahedron Lett. 2012, 53, 281. 
3. Santos, D. M.; Santos, M. M. M.; Moreira, R.; Solá, S.; Rodrigues, C. M. P. “Synthetic Condensed 1,4-
naphthoquinone Derivative Shifts Neural Stem Cell Differentiation by Regulating Redox State”, Mol. 
Neurobiol., 2013; 47, 313-324. 
4. Pereira, A. L.; Sureda, F. X.; Turch, M.; Amat, M.; Bosch, J.; Santos, M. M. M. “Synthesis of 
phenylalaninol-derived oxazolopyrrolidone lactams and evaluation as NMDA receptor antagonists”, 
Monatsh. Chem. (Special Issue: Young Investigators) 2013 (in press).  
64 
 
P14.  
Anomerisation of Glycosidic linkages using Titanium(IV) Chloride 
 
Farrell, M.P.; Murphy, P.V.* 
School of Chemistry, National University of Ireland, Galway, Ireland 
 
 
 
1,2-Cis glycosidic linkages are commonly found in naturally occurring molecules (e.g. KRN7000, 
heparan sulphate)  but are impart difficult to prepare by synthetic means. Thus far the 
utilization of non-participating protecting groups, the anomeric effect, solvent assisted 
glycosidations and various glycosyl donors have lead to respectable anomeric ratios in 
particular examples, but as of yet, a widely applicable and highly stereoselective method for 
synthesis of such linkages based on the above mentioned methodologies has not been 
achieved1.  
The Muphy group have previously shown the use of chelation induced anomerisation of 1,2-
Trans glycosidic linkages in the presence of acyl protecting groups as highly stereoselective and 
convenient route to the corresponding α-anomers2-4. Leading on from this we shall elaborate 
the utilization of this approach towards to the synthesis of various 1,2-Cis glycosidic linkages. 
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65 
 
P15.  
Camptothecin scaffold modification: synthesis and biology 
 
Michael S. Christodoulou,a Daniele Passarellaa 
a
Dipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133 Milano, Italy 
michael.christodoulou@unimi.it 
 
 
Camptothecin is a natural occurring pentacyclic quinoline alkaloid that was isolated from 
Camptotheca acuminata and is characterized by remarkable antitumor and antileukemia 
activity.[1] It acts as a selective poison of the nuclear enzyme topoisomerase I by forming a 
ternary complex with topoisomerase I and DNA.[2,3] The introduction of methylenthiol group at 
position 7 of camptothecin was carried out in four steps. This preparation also yielded the 
corresponding disulfide, which behaves as a prodrug due to its reactivity with glutathione. 
Assessment of their antiproliferative activities, investigations of their mechanism of action, 
and molecular modeling analysis indicated that the 7-modified camptothecin derivatives 
maintained the biological activity and drug-target interactions of the parent compound.[4]  
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The overall aim of this project is to identify mRNA based biomarkers by which melanoma cell 
lines can be classified according to their response to src inhibitors.  
For this purpose, by analyzing data from melanoma cell lines within two drug screening 
databases [1,2], we identified a gene signature consisting of 132 genes which could distinguish 
Saracatinib sensitive and resistant cells. A simultaneous analysis was performed to identify a 
"melanocyte signature" using two gene expression datasets, E-MTAB-783 and GSE36133; and 
yet a third one, based on genes functioning in invasion of melanoma [3]. Remarkably, 
clustering analysis of our samples performed individually for each of these three gene lists 
yielded the same two distinct clusters with almost the same samples within a given cluster. 
Thus, among our melanoma cell lines, low expressors of classical melanocyte markers such as 
Melan-A and Tyrosinase were classified as being Saracatinib sensitive. The same samples 
showed upregulation of genes involved in invasion suggesting that there is an oncogenic 
addiction of src protein in invasive melanoma cells. Results from ongoing in vitro experiments 
to validate predicted sensitivity profiles of the melanoma cell line cohort using both 
Saracatinib as well as two other scr inhibitors, Dasatinib and 10a, will be reported. Future 
experiments will include testing src activity in src inhibitor sensitive and resistant cells and 
determining the minimum number of genes by which sensitivity can be predicted by q-pcr. 
 
 
 
1. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, et al. (2012) The Cancer Cell Line 
Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607. 
2. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, et al. (2012) Systematic identification of 
genomic markers of drug sensitivity in cancer cells. Nature 483: 570-575. 
3. Jeffs AR, Glover AC, Slobbe LJ, Wang L, He S, et al. (2009) A gene expression signature of invasive 
potential in metastatic melanoma cells. PLoS One 4: e8461. 
 
 
 P17. 
Novel nanoassemblies of known anticancer compounds by coupling with 
Stella Borrelli
a 
Università degli Studi di Milano, Dipartimento di Chimica, Via Golgi 19, 20133 Milano (Italy)
b
 Università degli Studi di Torino, Dipartimento di Scienza e Tecnologia del Farmaco, Via Giuria 
On the base of our experience in the preparation of bivalent compounds in which two drug 
units are linked via a labile spacer able to release the active compounds
evaluate the possibility of linking two different compounds (a drug and a squalene tail) by a 
linker containing a disulfide bond. In fact, the presence of the squalene moiety could allow the 
formation of nanoassemblies in water, facilitating the uptake of the conjugates by cells
fact, nanoparticles represent an interesting opportunity, being abl
agent from its biological environment
undergo a disulfide exchange reaction in the intracellular environment, thus releasing the 
active drugs.  
On this purpose, we prepared a small c
to be able to self-assemble in water. The nanoassemblies have been characterized for what 
concerns the mean diameter, the Z potential and the polydispersity index. Compounds 
Tax(2’)-Sq were also submitted to an Atomic Force Microscopy (AFM) analysis.
We also tested the chemical stability of the disulfide bond in the presence of glutathione (GSH) 
and, after a mass spectrometry experiment, we found that our compounds are able to release 
the active drugs. A similar experiment carried on nanoparticles revealed that also in its case 
the active drug has been released.
A preliminary evaluation of the cytotoxicity of our compounds has been effected against MCF
7 cell line, and some of them showed a good ac
In the end, the interaction of compounds 
immunofluorescence analysis.
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The function of many proteins involved in self-renew and tumorigenesis rely on their 
nucleocytoplasmic transport including FOXO proteins, p53, Stat3 c-Myc and Sox-2. Therefore 
specific inhibition of nucleocytoplasmic transport has been considered as an attractive 
anticancer strategy. In order to inhibit this fundamental cellular process we propose to study 
the molecular strategies used by several viruses to prevent the antiviral response of the host 
cell by blocking the nuclear import of cellular proteins. We have performed a systematic 
survey of available data on viral proteins that interfere with the cellular machinary 
nucleocytoplasmic transport. Viruses capable of interfering with nucleocytoplasmic transport 
include Venzuelan Equine Encephalitis, Rotavirus Poliovirus, Rhinovirus, Ebola Virus, Influenza 
Virus, Foot-and-mouth Disease Virus and Vesicular Stomtitis Virus. Specific proteins from these 
viruses have been shown to interact with cellular proteins such as Nup62, Nup98 Nup153, 
Nup214, eIF4E, Rae1 and p65 (RelA). Amino acid sequence information of the corresponding 
viral proteins can be used to design short peptides or peptidomimetics to be analyzed for their 
capacity to interfere with the nucleocytoplasmic transport of cancer relevant cellular proteins. 
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